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Recommendation: Buy  Gerresheimer AG 
Current price as of May 8th, 2019: 69€  Healthcare / Pharma 
Price Target: 78€  Reuters: GXIG.DE 
  
Investment Summary 
Growing…. slowly, but surely 
 
After rough years, the new CEO puts Gerresheimer back on 
“growth-path” and presents a promising mid-term outlook. I 
therefore issue a buy recommendation targeting a price of 78€, 
which represents an upside potential of 15% compared to a 
current share price of 69€ as of May 8th, 2019. When comparing 
it to the price as of valuation date (63€) the upside potential 
amounts to 24%. Gerresheimer gets tailwind from stable 
industry and macroeconomic outlooks and will particularly 
profit from arising megatrends.  
Strong year 2018 and even stronger mid-term guidance 
2018 was strong with an adjusted EBITDA of 294 EURm and 
sales of 1.433 EURm on a group basis. The valuation based on 
its individual parts, PPG and P&G, and its newly acquired 
Advanced Technologies division, result in an EV of 3.617 
EURm. EBTIDA-margins average at 20% and sales forecast of 
its core-business is projected at 2-3%, leaving space for positive 
surprises. 
Trust in the new Management 
The new CEO radiates confidence as well as optimism and has 
structured ideas on how to improve Gerresheimer´s operational 
performance, productivity and geographical footprint. Dietmar 
Siemssen, seems capable of transforming the Advanced 
Technology unit into a strong part of Gerresheimer and of 
escaping the pressure on margins arising from the 
competitiveness of the contract manufacturer business. 
Gerresheimer presents an attractive investment in the light of 
pharma growth, megatrends and promising projects arising from 
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€m 2018 2019 2020
Revenue 1.355     1.397     1.435     
EBITDA 274        269        279        
Net Income 139        81          83          
ROIC 10,5% 5,9% 5,9%
FCF 126        63          68          
Business Unit EV (€m)
EV Advanced Technologies 335        
3.282     
2y EV/EBITDA 13,5x
Fianancials: PPG & P&D
Profile
Sum of the parts Valuation









52-week high 79,9 14.09.2018
52-week low 51,3 04.01.2019
1-year change 1,13% March 18-19





This master thesis performs an equity valuation of Gerresheimer AG, a global manufacturer for 
the pharma and healthcare industry, and determines its ordinary share price as of 30.11.2018. 
 
The state-of-the-art valuation approaches are presented and the industry- and macroeconomic 
environment of Gerresheimer is analyzed. Afterwards, the equity value of Gerresheimer is 
determined using the sum of the parts DCF approach, combined with a relative valuation 
consisting of trading multiples. The Advanced Technologies division of Gerresheimer is valued 
based on the fair market value of the purchase price. 
 
The author issued a buy recommendation with a target price of 78€ as of Nov 30, 2018, with an 
upside potential of 24% compared to a share price of 63€ as of Nov 30, 2019. The results are 
subject to a sensitivity analysis, consisting of different scenarios and variations of 
Gerresheimer´s expected operating performance, completed with a Monte Carlo analysis.  
 
Finally, the methodologies and results are compared to the equity report provided by Credit 
Suisse, a leading multinational investment bank. 
 
Author: Martin Kreuzer 
Title: Equity Valuation of Gerresheimer AG  
Keywords: Equity Valuation, share price, Enterprise Value, Corporate Finance, 





A problemática da presente Tese de Mestrado consiste na avaliação do capital próprio da 
empresa Gerresheimer AG que, sendo um produtor a nível global, atua nas indústrias 
Farmacêutica e de Saúde. O preço das ações ordinárias da referida empresa é infra determinado 
à data de 30.11.2018. 
 
Distintas metodologias de avaliação são apresentadas, bem como uma análise da indústria e do 
ambiente macroeconómico em que se insere a Gerresheimer. Seguidamente, o valor do capital 
próprio da empresa é calculado através da combinação de duas abordagens: DCF (soma das 
partes) e avaliação relativa recorrendo a múltiplos de transação. O valor da divisão de 
Tecnologias Avançadas da Gerresheimer é determinado com base no justo valor de mercado do 
preço de aquisição. 
 
O autor apresenta uma recomendação de compra a um preço-alvo de 78€ à data de 30.11.2018, 
com um potencial de retorno de 24% comparativamente com o preço por ação de 63€ a 30 de 
novembro de 2018. Os resultados obtidos foram sujeitos a uma análise de sensibilidade relativa 
a diferentes cenários expectáveis da performance operacional da Gerresheimer, análise essa que 
é complementada com uma análise Monte Carlo. 
 
Finalmente, as metodologias e resultados são comparados ao relatório de capital próprio da 
Gerresheimer AG emitido pela Credit Suisse, um banco de investimentos líder multinacional. 
 
Autor: Martin Kreuzer 
Título: Equity Valuation of Gerresheimer AG 
Palavras-chave: Avaliação de Ações, Cotação, Valor da Empresa, Finanças Corporativas, 
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The aim of this Master Thesis is to assess the Equity Value of Gerresheimer AG as of 
30.11.2018. 
Gerresheimer has a long history in providing specialty glass and pharmaceutical plastic 
products for global healthcare companies and in improving health and well-being of society. 
Gerresheimer and its industry are struggling to manage financial, societal and organizational 
challenges and face an environment that is currently shaped by digital technologies, aging and 
growing population and increases in chronic diseases. Changes bring opportunities that will 
help companies to deliver new healthcare models and to find the balance between financial 
stability and providing affordable as well as accessible products to society. 
Gerresheimer missed the growth expectations of investors in the past and time will show 
whether the company can tackle the opportunities and become an attractive investment 
opportunity or whether it falls behind. This thesis will elaborate the impacts of its environment 
and will provide a unbiased perspective of Gerresheimer´s equity value.  
1.1 Research questions and structure  
The report answers the following research questions: 
What are the most accurate valuation-approaches to determine Gerresheimer´s equity value? 
How will the industry and macro-environment influence Gerresheimer´s fair value? 
What is the fair value of one common share of Gerresheimer as of 30.11.2018? 
What is the expected upside/downside potential? 
To answer the research questions, first a presentation of the state-of-the-art valuation 
methodologies is provided in the literature review. Secondly, Gerresheimer´s industry and 
macroeconomic environment are analyzed and evaluated. Thirdly, the financial performance is 
projected based on Gerresheimer´s past performance and on the adjustments made to the 
consolidated statements. Adjustments are necessary given Gerresheimer´s previous acquisition 
of Sensile-Medical. Finally, the fair value will be determined, using the most accurate valuation 
approaches, and compared to the equity report provided by Credit Suisse. 
Literature Review 
2 
2 Literature Review 
The following chapter provides an overview of the three most common valuation techniques 
used to value publicly listed company. Firstly, the relative valuation approach, that values the 
asset based on prior transactions or comparable company multiples. Secondly, the Discounted 
Cash Flow Valuation (“DCF”), that is valuing a company based on its expected future cash 
flows. Lastly, the contingent claim valuation, that uses option pricing models to analyze the 
value of an asset. (Damodaran, 2010) 
2.1 Relative Valuation Techniques 
In a multiple valuation, the target company is valued using precedent transaction multiples 
(“transaction comps”) or comparable company multiples (“trading comps”). The former is 
mainly applied in M&A-transactions or restructuring deals and is based on the acquisition price 
paid by the buyer for similar companies in prior transactions. As this valuation technique 
contains a premium paid, which is described as a reflection of the value investors pay to fully 
control a business, a more common approach used by equity analysts are trading multiples. This 
methodology assumes that companies in the same sector and with comparable financial ratios, 
provide a relatively similar equity value of the target company. (Rosenbaum et al., 2009) 
For the purpose of this thesis, a trading comps analysis will be conducted. In order to do so, a 
peer group has to be selected together with its financials, which is, in a next step, applied to the 
target financials to drive a valuation range. (Lie & Lie, 2002) 
Multiples are an easy and widely recognized way of estimating a current and market-based 
enterprise/equity value of the target company and particularly useful when combining it with a 
DCF analysis (Kaplan & Ruback, 2007). However, they also come with drawbacks, as they are 
subjective in terms of market conditions and might lead to skewed valuation results (e.g. in 
bearish or bullish markets). Furthermore, there might be no relevant comparable companies that 





2.1.1 Peer Group 
The basis of the multiple analysis is the selection of the right portfolio of comparable companies 
(i.e. peer group). Valuation practice recommends selecting the peers based on business and 
financial related criteria. Particularly, Kaplan & Ruback (2007) describe that “comparables” 
should bear a resemblance to the target in terms of cash flow growth projections, risk structures 
and performance indicators. Appropriate measures that will be used in this thesis include 
“ROIC” (Return on Investment), “EBITDA margin” (Profitability) “Net Debt/EBITDA” 
(Leverage ratio), “Sales CAGR (5y)” or “EBIT/Interest expenses” (coverage ratio).  
2.1.2 Most commonly used Multiples 
Selecting the right multiples is a broadly discussed topic in finance literature. Kim & Ritter 
(1999) argued that, “there is no clear answer for which multiples should be used”. According 
to a research of Morgan Stanley (1999) the most common multiples are Price-to-Earnings (PE) 
and EV/EBITDA. In general, multiples can be based on Equity Value, Enterprise value and 
on growth measurements: (Fernández, 2001) 
 PE = Market Cap/Total Net Income  
 
EV/EBITDA = Enterprise Value/EBTIDA 
EV/EBIT = Enterprise Value/EBIT 
EV/Sales = Enterprise Value/Sales 
 
 PEG = PE/growth of Earnings per Share (5y)  
Table-1: Most commonly used multiples 
Multiples based on Equity Value reflect the price equity investors are willing to pay for each 
euro of earnings. It represents one of the most popular multiples but comes with some 
limitations; net income includes interest expense and is, therefore, dependent on the capital 
structure of a company. Furthermore, it is subjective to accounting regulations (e.g. for D&A 
and taxes) which might lead to misleading results when comparing with its peers. (Damodaran, 
2010) 
By contrast, Enterprise value refers to the claims of both, equity and debt holders and is used 
in line with unlevered financial metrics (e.g. EBITDA, EBIT, Sales). Although widely used, 
EBITDA multiples do not take into consideration capital expenditures, that are linked to D&A, 




Lastly, growth Multiples are similar to the enterprise- and equity multiples, but additionally 
take the growth rates of certain parameters into consideration. They usually find their 
application in rapidly growing industries. (Fernández, 2001) 
Studies based on companies listed on US-stock exchanges, showed that multiple valuations 
perform best when using forward multiples (e.g. 2 years horizon) derived from analyst’s 
expectations. Compared to historical data, they are more accurate and relevant when computing 
the company´s value. (Liu, 2002)  
2.2 Intrinsic Valuation – Discounted Cash Flow 
The most fundamental valuation methodology is the Discounted Cash Flow Analysis, which is 
built on the assumption that the “value of a company today equals the value of its projected 
Free Cash Flows, discounted at an appropriate rate”. (Kaplan et al., 1995) The approach is based 
on several mainstays and assumptions: 
2.2.1 Framework of Free Cash Flow Models  
The main Free Cash Flow Methods are Free Cash Flow to the Firm (“FCFF”) and Free Cash 
Flow to Equity (“FCFE”). The former represents the Cash Flow available to all funding 
providers (equity and debt investors) after accounting for all cash operating expenses, taxes, 
capex and working capital. (Mielcarz & Mlinarič, 2014) 
Earnings Before Interest and Taxes (EBIT) 
(-) Taxes on EBIT 
(=) Net Operating Profit Less Adjusted Taxes (NOPLAT) 
(+) Depreciation & Amortization (D&A) 
(-) Capital Expenditures (Capex)  
(+/-) Changes in Net Working Capital (NWC) 
(=) Free Cash Flow to the Firm (FCFF) 




The FCFE is a metric measuring the amount of cash available to equity holders only: 
Net Income (NI) 
(+) Depreciation & Amortization (D&A) 
(-) Capital Expenditures (Capex) 
(+/-) Changes in Net Working Capital (NWC)  
(+) Net Borrowings  
(=) Free Cash Flow to Equity (FCFE) 
Table 2: FCFE Derivation; (Berk & DeMarzo, 2014) 
2.2.2 Weighted average cost of capital 
The standard approach to continue the intrinsic valuation of the target is to discount the 
projected Free Cash Flows using the weighted average cost of capital (“WACC”). The WACC 
is based on the company´s current capital structure and represents the weighted average of the 
cost of capital of the target. Particularly, it is a measure of how much return investors are 
expecting on debt and equity, depending on the current market situation. (Arditti, 1973; Bruner 
et al., 1998). 






   
kd Cost of Debt ke Cost of Equity 
t Tax rate E Market Value of Equity 
D Market Value of Debt V D+E 
Equation-1: WACC-computation 
 
2.2.2.1 Cost of Equity 
The Cost of Equity describes the return that investors are expecting to receive to compensate 
for the risks of owing an asset. The most common methods for valuing those risk are the Capital 
Asset Pricing Model (“CAPM”), the Arbitrage Pricing Theory (“APT”) and the Fama-French 
three-factor model. (Damodaran, 2012) For the purposes of this thesis, the CAPM will be used 
for the valuation of Gerresheimer and will therefore be explained in more detail: 
Literature Review 
6 
In general, an investment bears two risks: the “systematic” and the “unsystematic” risk. The 
former refers to potential market risks (e.g. war or recessions) and cannot be diversified away. 
There will always be the presence of those risks and thus the investors should receive 
compensation. On the contrary, the unsystematic risk refers to a specific asset and will not be 
compensated in the CAPM as it can be diversified away. (Black et al., 1972) 
𝑘𝑒 = 𝑟𝑓 +  ßL ∗ (𝑟𝑚 − 𝑟𝑓) 
ke Cost of Equity rm Expected rate of return on Equity 
rf Risk Free Rate (rm-rf) Market Risk Premium 
ßL Levered Beta   
Equation-2: CAPM computation 
 
The risk-free rate reflects the return investors would expect from an investment with zero risk. 
Therefore, the entity issuing the risk-free security should not have a default- or a reinvestment 
risk. German or US Government Bonds are generally recognized as being riskless. The risk-
free should be in line with the currency of the free cash flows as well as the time horizon 
assuming a going concern of the target. For practical reasons, usually a risk-free rate with a 
maturity of 10 years is used. (Bruner et al., 1998) 
The Market Risk Premium (“MRP”) represents the return investors demand over the risk-
free to compensate for the volatility in the total equity market. It is seen as the delta between 
the expected return on equities and the risk-free rate. The CAPM suggests, that the premium 
should reimburses the investors for the systematic risk that any investments bears. (Fama, 1968) 
Given the lack of clear consensus on how to compute the MRP, a rate of 5,5-7,0% should 
currently be applied in Germany according to the institute of auditors (Zwirner, 2018). 
According to Damodaran (2019), the MRP in Germany is 6%. 
Beta (Levered and unlevered) is a measurement of the systematic risk of a company and 
indicates whether the asset is more/less volatile than the whole market. It states how sensitive 
the asset´s return is compared to the market and can be expressed as “the covariance between 
the rate of return on the company´s stock and the market return”. A beta greater than 1.0 means 
that the asset is more volatile and has a higher systematic risk (and v.v.). (Rosenbaum et al., 
2009) As the beta is reversing around the mean (“1” for the market) the raw betas should be 











Equation-3: Blume adjustment 
The unlevered Beta (ßu) refers to a company without taking the effects of financial leverage 
into consideration. On the other hand, the levered beta (ßL) considers the impact of the 







                            ß𝐿 = ß𝑢 ∗ (1 +
𝐷
𝐸
∗ (1 − 𝑡)) 
ßL Levered Beta t Tax Rate (effective)  
ßu Unlevered Beta D/E Debt-to-Equity ratio 
Equation-4: Beta levered/unlevered 
The unlevered Beta is “relevered” using the target´s capital structure and effective tax rate. The 
levered Beta is then used in the CAPM to compute the cost of equity. (Damodaran, 2012) 
Country risk premium: Adding a country risk premium to the cost of equity is a concept 
developed by (Damodaran, 2012) to adjust for additional risks of equity markets. In 
Gerresheimer´s case, no additional risk premium will be added as the company is considered 
as well diversified given that it generates most of its sales in Europe. Furthermore, its 
production facilities (assets) are mainly in “low-risk” countries.  
2.2.2.2 Cost of Debt 
The second main input for the WACC is the cost of debt, which reflects the costs at which a 
company can borrow on the capital market given the company´s credit profile and D/E ratio. 
The cost of debt can be derived by the yield of the outstanding debt instruments of the target. 
(Rosenbaum et al., 2009) 
In the case the company has no regularly traded bonds outstanding, the cost of debt can be 
calculated using the targets credit rating (e.g. derived from Moody´s, S&P or Fitch-Ratings) 
and the associated credit spread. (Rosenbaum et al., 2009) 
However, some companies are not rated by rating agencies. (Moody´s, 2018) In this case, a 
synthetic rating can be applied using interest coverage ratios (EBIT[DA]/interest expenses) and 
compare it to the rating classes developed by investment banks or Damodaran. To finally derive 
the cost of debt, the risk-free is usually added to the credit spread. The credit spread itself is 
difference between two bonds with similar maturity but different credit quality. (Damodaran, 
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2012) As Gerresheimer has neither traded bonds outstanding nor is rated by agencies, the 
above-mentioned approach will be applied.  
As debt is tax-deductible, the WACC captures the after-tax cost of debt by applying a tax-shield 
using the following formula: 
𝑎𝑓𝑡𝑒𝑟 𝑡𝑎𝑥 𝑘𝑑 = 𝑝𝑟𝑒 𝑡𝑎𝑥 𝑘𝑑 ∗ (1 − 𝑡) 
Equation-5: Tax-shield 
Therefore, the after-tax costs are lower than the pre-tax costs and this benefit increases as the 
tax rate increases. (Damodaran, 2012) Some countries, however, may limit the deduction of net 
interest expenses on taxable income up to a certain level, which should be taken into 
consideration when computing the WACC. (Schmidt & Moesle, 2018) 
2.2.3 Terminal Value 
The terminal value (TV) is a metric used to capture the value of the target beyond the explicit 
period and is based on last year´s FCF. In general, one can differentiate between the Exit 
Multiple Method (“EMM”) and the Gordon Growth Model (“GGM”). (Rosenbaum et al., 2009) 
Gordon Growth: 
𝐹𝐶𝐹𝑛 ∗  (1 + 𝑔)
(𝑊𝐴𝐶𝐶 − 𝑔)
 
g Growth Rate (e.g. nominal GDP growth rate) 
FCFn Last year of the projection period  
Equation-6: Perpetuity growth model 
 
The GGM was originally developed by Myron Gordon and Eli Shapiro in 1956 and is best used 
for mature companies that reached the steady state. (Gordon & Shapiro, 1956)  
For the purposes of this thesis, the last year of the explicit period will be extended for the 
Terminal Value year in order to make necessary adjustments. Thus, the perpetuity formula will 




Exit Multiple Method:  
𝐸𝐵𝐼𝑇𝐷𝐴𝑛 ∗ 𝐸𝑥𝑖𝑡 𝑀𝑢𝑙𝑡𝑖𝑝𝑙𝑒 
EBITDAn EBITDA of the last projection period 
Equation-7: Exit Multiple Method 
Although appreciated by bankers, the mix of intrinsic (DCF) and relative approach (EMM) does 
lead to inconsistency in the valuation. To avoid potential irregularity, it is suggested to project 
the TV using the GGM. (Damodaran, 2012) 
2.2.4 Present Value Calculations 
The calculation of the Present Value of the FCF lies on the principle of the Time Value of the 
Money. This concept goes back to the Jewish theology and to Babylonian Talmud (ca. 500 CE) 
who first argued that the benefit of receiving money today is higher than receiving it tomorrow. 
Based on this reasoning, the projected FCFs and the TV are discounted to their present values 
using an appropriate discount rate. (Fernández, 2007b; Peterson & Fabozzi, 2009) The discount 
rates differ dependent on the Framework of the FCF: 
Methodology Discounting Method 
FCFF Weighted Average Cost of Capital 
FCFE Levered Cost of Equity (ßl) 
APV Unlevered Cost of Equity (ßu) 
Table-2: Discounting methods of Intrinsic-valuation-methodologies (Koller et al., 2015) 
 
2.2.4.1 Enterprise- and Equity-Discounting Models 
The most common way to compute the DCF Model is to discount the projected Free Cash Flows 















Alternatively, one can discount the FCFE with the levered cost of equity which derives the 
equity value of a target. The relationship between the enterprise value and the equity value can 
therefore be described as the following equation: (Rosenbaum et al., 2009) 




A company that operates in different segments might be valued based on the sum of the values 
of its divisions. (Fernández, 2007a) This approach allows to take different risks, capital 
structures and economic profiles into consideration. (Pinto et al., 2010) For the purpose of this 
thesis, this method will be applied to account for the impact of the newly acquired Sensile-
Medical division.  
2.2.4.3 APV 
An alternative to the above-described approaches is the Adjusted Present Value Model 
(“APV”). It separates all elements of the company’s value and analyses each one of them in a 
separate step. Hereby, it uses the unlevered cost of equity to discount the free-cash-flows. 
Further, it calculates the net value of debt (e.g. tax shields, bankruptcy costs or subsided 
financing) and adds it to the “all-equity financed” enterprise value. This approach follows the 
assumptions of Modigliani & Miller who described that, “in a perfect capital market, the capital 
structure does not affect the value of a company”. (Miller, 1988; Myers, 1974)  
The concept of APV is widely recognized and appreciated although rarely used by Investment 
Banks. One reason for that might be that investment bankers do not feel comfortable valuing 
the expected bankruptcy-costs, a main component in the APV, for their clients. While direct 
bankruptcy costs have been studied and can easily be measured, there is not much evidence on 
how to evaluate the indirect costs of bankruptcy. For example, losses resulting from the fear of 
stakeholders if bankruptcy becomes more likely. They will start abandon the firm as they 
believe their claims will not be settled, which will lead in declining profitability and 
consequently making filing for bankruptcy more likely. (Sautner & Vladimirov, 2013) Given 
that drawbacks, and the stable capital structure of Gerresheimer, this concept is not applicable 
for this thesis.  
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2.3 Contingent Claim Valuation 
The basic idea of the contingent claim valuation is that securities sharing the same 
characteristics as options, can be valued as options. An asset is an option once it derives its 
value from an underlying asset and once its cash flows are dependent on the appearance of 
specific events. The “owner of a real option has a right, but not the obligation, to execute certain 
business activities (call option) or to not execute them (put option)”. Business activities as such 
can be M&A, restructuring deals or other investments that meet the criteria of an option. (Koller 
et al., 2015) 
As the Contingent Claim Valuation is not applicable in Gerresheimer´s case, it will not be 
further discussed in this thesis.  
Market Conditions 
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3 Market Conditions 
A critical part of any equity valuation is the assessment of the macroeconomic performance and 
the industry the target company is operating in. After providing a macroeconomic analysis, this 
chapter identifies the main drivers of the “medical equipment, supplies and distribution 
industry” and the overall “healthcare” sector:  
3.1 Macroeconomic Overview 
Current research articles of Goldman Sachs (2019) and the International Monetary Fund, 
(2019b) have elaborated that the global economic strength is anticipated to decrease slightly 
from 3,7% in 2018 to 3,5% in 2019 and 3,6% in 2020. The global forecast for the years 2019 
and 2020 has previously noticed a downward correction with further corrections being expected 
due to the “trade-war” between US and China. (IMF, 2019b) The EU also faces a range of 
potential risks in 2019 in the light of a disorderly Brexit, Italians Budget crisis and threats 
emitted from the US Administration as well as general trade tensions. Therefore, the European 
Central Bank remains its pro-active growth policies leading to an expected Euro-area growth 
of 1,6% in 2019. (IMF, 2019b; Hatzius et al., 2019) In the long run, the Euro-area and 
particularly Germany, are expecting to suffer a slowdown in real GDP growth, meaning that it 
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Figure-1: Real GDP growth from 2000-2023 as of October 2018, (IMF, 2019b) 
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When looking at the Emerging Markets, one can see that the GDP growth rate1 remains rather 
flat while the inflation rate2 is expected to decrease significantly by 2% till 2023. Heavily 
contributing to EM´s slowdown is China; the People´s Republic is suffering from fears of more 
damaging trade war and further decreases in domestic demand growth. Political uncertainties 
in Brazil also caused a slowdown in EM`s growth forecast. (IMF, 2019b; Hatzius et al., 2019) 
 
In line with ECB´s growth fostering policies, the low interest rates are expected to remain 
unchanged since 2016. This further results in slight increases in the euro-inflation rate which is 
aimed to reach a level of 2%. (ECB, 2019) A higher inflation rate can be seen when looking at 
Europe and Germany, where the rate is expected to reach up to 2,4% and 2,2% respectively 
until 2023. A different pattern can also be monitored in North America; the lasting low gasoline 
prices put pressure on the inflation rate, which will remain flat throughout the explicit period. 
(IMF, 2019a)  
                                                          
1 Average of the Emerging Markets Gerresheimer is operating in 
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Figure-3: Risk-free rate development (FRED, 2019) 
As the German government bond (10-years) will be used as a risk-free rate for WACC purposes, 
Figure-3, illustrates the historical development until March-19. For the last 10 years, but also 
since the early 90s, the rate has experienced a notable downward trend. 
3.2 The Healthcare Equipment and Supplies Industry 
Gerresheimer is operating in the “Healthcare Equipment & Supplies Industry” - a sub-industry 
of the “Healthcare Services and Equipment- and the Healthcare sector”. (Gerresheimer, 2019) 
Given it´s dependency on the sector, it is worth to analyze the dynamics and drivers of this 
segment as well. A focus will lie on megatrends and impacts that will shape the packaging 
industry, completed by a Porter´s five forces analysis. (Appendix-1)  
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3.2.1 Trends and Developments 
Total revenues for the industry amount to roughly 350 USDbn in 2019 and expected to growth 
by 18% within the next 5 years. Their underlying growth is mainly triggered by megatrends, 
technological improvements, increased healthcare access in emerging countries, and generic 
market growth (MarketLine, 2019). The biggest players as illustrated in Figure-5, are the 
Medical-Devices division of Johnson & Johnson and Thermo-Fisher. 
 
Figure-5: Main industry-players (Reuters, 2019; own computation) 
3.2.1.1 Megatrends 
The pharma and healthcare sector are dependent on several economic and demographic 
developments mainly triggered by the so-called “megatrends”. Particularly, the sector is 
benefitting from improvements and access of medical supplies in less developed areas and 
boosts in demand due to the “rise in chronic diseases, aging population, increase in global life 
expectancy, rapid growth in generics and growing trends towards self-medication”. Chronic 
diseases, as for example diabetes, a major core competency of Gerresheimer, are expected to 
affect more than 630 Million people until 2040, compared to 425 Million in 2018 according to 
latest research of the World Health Organization. (WHO, 2018) These figures go in hand with 
the overall aging population; according to the United Nations, the number of people aging over 
80 is expected to triple within the next 30 years. (UN, 2017) These demographic developments 
foster demand, revealing a great spectrum of possibilities in the industry. (Gerresheimer, 2019)  
Other trends and changes in the industry radiate from technological improvements such as 




























in the business strategy, these developments can improve productivity on the supply side and 
reduce the cost of packaging. New technologies are forcing the market players to redefine 
innovative approaches in order to tackle new arising customer needs. However, strict network 
of regulations in the sector (Good Manufacturing Process Regulations) might harm the pace in 
which innovation occurs and will make it difficult to effectively reduce production costs. 
(Radhakrisnan, 2019) 
3.2.1.2 Further prospects and outlooks 
Not only demographic developments and new technological inventions are going to shape the 
industry: The FDA is expected to accelerate the approval process of pharmaceuticals allowing 
players to increase their product development process. The IQVIA Institute (2019) predicts the 
number of new products released per year to increase from (on average) 46 in the last 5 years 
to roughly 54 in 2023. This volume increase is triggered by new developed biotech and 
biosimilar products. (Aitken, 2019) 
As illustrated in Figure-6, the overall global pharmaceutical market is expected to report a 
CAGR of 2,2% from 2019 to 2023 and 3,7% for the Pharmerging3 Markets (“PM”) in the same 
period, generics are expected to grow on average 2,9% globally and 4,9% in the PM´s in volume 
per year till 2023. Although, the pharma sector will perform slightly inferior than expected, the 
sector is considered as being less affected by economic downturns and will profit from 
demographic developments triggered by the increasing global life expectancy. (Aitken, 2019; 
Passport, 2019) 
                                                          
3 Pharmaceutical market activities in Emerging countries  
Figure-6: Pharmaceutical-market CAGR 2019-2023; (Passport, 2019; Aitken, 2019) 
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3.2.2 Energy- and commodity prices 
As the industry is highly dependent on energy and commodities resources, it is worth analyzing 
their expected development.  
According to Reuters (2019), natural gas and crude oil are expected to remain at a low level 
after the drop that followed the high at the end of October 2018. Partly responsible for the 
decrease is the remaining high supply.  
According to Management, Gerresheimer hedges up to 65% and limits the exposure on 
commodities significantly. (Gerresheimer, 2019) Furthermore, specific contracts often allow 
the producers to pass on price increases to the customer. Likewise, decreases in commodities 
are passed on to the customer, making changes in the long-term (e.g. in perpetuity) expected to 
off-set each other. Lastly, country specific regulations often allow energy-intensive businesses 




4 Company Overview 
Gerresheimer is a global partner of pharmaceutical and healthcare companies, providing special 
glass and plastic products for the use of pharmaceutical and healthcare packaging. The company 
is based in Düsseldorf, Germany, and generated revenues of 1,4 EURbn in 2018 and a net 
income of 131 EURm, through its “Plastic & Devices”, “Primary Packaging Glass” and 
“Advanced Technologies” division. At the end of the fiscal year 2018, the company had 9890 
employees and managed 44 production operations in 15 countries in Europe, America and 
Asia4. (Gerresheimer, 2019) Appendix-2 presents a concluding SWOT-Analysis. 
The company was founded as a glassblowing business in 1864 and became the world’s largest 
glass bottle producer by 1886. In 1888, Gerresheimer took on the legal form of a joint stock 
company and moved into the pharmaceutical glass production business a hundred years later. 
After several restructuring activities, the company managed to get a foothold in the production 
of plastic systems. In July 2007, Gerresheimer was taken public by Blackstone, the owner at 
that time, who then completely withdrew from the company. Since December 2008, 
Gerresheimer is listed in the MDAX, the mid-cap stock index of German companies. 
(Gerresheimer, 2019). 
                                                          
4 a list of countries is provided in appendix-17 
Figure-7: Production Facilities (Gerresheimer, 2019) 
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Recently, the following valuation relevant events occurred: 
4.1 Divisions 
Gerresheimer is operating through three divisions (Gerresheimer, 2019): 
• The Plastic & Devices division includes products for simple and safe drug delivery made 
of plastic. The most common products are for example “insulin pens, inhalers, nasal spray 
vials and pharmaceutical plastic containers”.  
• The Primary Packaging Glass unit covers the packaging made of glass for medicines and 
cosmetics as “jars, ampoules, perfume flacons and special glass containers”. This segment 
also delivers the food & beverage industry by serving bottles, customized vails and jars.  
• The Advanced Technologies (“Atech”) division was established through the acquisition 
of Sensile-Medical, a Swiss based Tech-company, in 2018. Currently, this unit offers 
“micro-pumps used for self-medication for Diabetes or Parkinson”. 
When observing the overall drug value chain, as illustrated below, one can see that 
Gerresheimer is positioned as a packaging manufacturer and first involves with the client 
roughly three years before commercialization. The lack of the ability to support throughout the 
whole value chain, as compared to an “integrated solution provider” might hinder the company 
to address customer´s needs successfully through in-house R&D services. (Halitsa, 2019) With 
its new division, Gerresheimer is trying to get involved with the customer at an earlier stage, 
aiming to achieve more lucrative customer relationships particularly in the generics-market and 
bio-solution business. (Gerresheimer, 2019)  
November 1, 2018New CEO
• Dietmar Siemssen was appointed as the new CEO of Gerresheimer.
July 11, 2018Sensile-Medical
• Acquisition of the Swiss technology company and creation of a new divison, 
"Advanced Technologies". The division is part of the Q3 consolidated Statements 
and will, for valuation purposes, be excluded from the 2018 financial statements.
September 1, 2015Centor
• The plastic container  producer is the biggest acquistion in company history.  
Consequently, Gerresheimer´s consolidated financial statements increased signficiantly 
after incorporating Centor´s accounts. 




Figure-9: Simplified Drug Value Chain (Halitsa, 2019) 
 
4.1.1 Share price development 
Table-3 illustrates Gerresheimer´s stock, the MDAX, as well as the performance of the 
healthcare sector between Q1 2014 and Q1 2019. 
Period Gerresheimer MDAX Healthcare Sector 
Q1 2018 - Q1 2019 1,13% -4,50% -9,18% 
Q1 2017 - Q1 2018 -10,22% 7,06% -9,23% 
Q1 2014 -Q1 2019 43,48% 48,47% 48,88% 
Table-3: Changes of Gerresheimer Stock, MDAX and the Healthcare Sector (Reuters, 2019) 
At the beginning of the period (March 2014), Gerresheimer´s stock stood at 47 € and increased 
to roughly 67 € after 5 years, despite some slight setbacks. Looking at the previous year, the 
stock increased by 1,1%, with trading volume remaining constant at a level of 119.286 shares, 
compared to a growth rate of -9,2% of the overall healthcare sector.  
 
 
Final assembling of the drug / device
Further production and life cycle  management
Commercial production (high volume)
Production of pilots (very low volume)
Designs and developments of the product






Uncertainties derived from the “Brexit” and lingered trade tensions put a pressure on the stock, 
but Gerresheimer still managed to outperform its benchmarking indices. Between Q1 2014 and 
Q1 2019, the MDAX head towards 24.440 starting from 16.462 points. Nonetheless, the index 
could not escape the negative environmental conditions and experienced some drawbacks in 





4.1.2 Shareholder Structure 
100% of Gerresheimer’s shares are currently in free-float, according to the criteria of 
“Deutsche-Börse”. The three main shareholders hold around 15,4% of the total 31,4 million 
shares, as per January 18, 2019 (Gerresheimer, 2019).  
Company Share in % 
NN Group 5,20% 
Stichting Pensioenfonds ABP 5,10% 
BNP Paribas Investment Parnters S.A. 5,07% 
Table-4: Gerresheimer´s main shareholder (Gerresheimer AG, 2019) 
4.1.3 Historical Performance 
The historical performance will be analyzed from 2014-2018 to make sure the whole business 
cycle of Gerresheimer is captured and will illustrate the impacts of the Sensile-acquisition. The 
consolidated Income Statement and Balance Sheet as reported, as well as necessary “Sensile-
adjustments”, are provided in appendix-3 & 4.  
If not stated else, all data/information is taken from Gerresheimer´s annual reports (2014-2018). 
  
Figure-10: Gerresheimer share price MDAX-benchmarking 
(Reuters: March 19, 2019) 
Figure-11: Gerresheimer share price Healthcare-
















































































































Gerresheimer share price vs. MDAX
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Q1 14 - Q1 19
Gerresheimer AG Healthcare Index
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4.1.3.1 Sensile-Medical Acquisition 
In Q3 2018, Gerresheimer acquired Sensile for a maximum consideration of 335 EURm 
(161 EURm initial payment, 174 EURm allocated as liabilities; payment subject to milestones 
over the next 3 years). As the acquisition is assumed to be at fair-value, the maximum of the 
purchase price of 335 EURm represents the enterprise value (value of eebt and equity) of Atechs 
as of 30.11.2018. 
 
Figure-12: Allocation of max. consideration transferred (Gerresheimer, 2019) 
As the company only presents its accounts on a consolidated basis, Sensile’s figures will be 
deducted from the 2018 statements in order to present its impact.  
4.1.3.2 Revenue performance 
In 2018, Gerresheimer generated more than half of its total sales in Europe (56%) -including 
Germany – followed by North America and the Emerging Markets. Germany is the most 
important segment with a contribution to overall revenues of 22%. More detailed figures are 
attached in the appendix-5. 
Figure-13: Revenues by geography 2014-2018 (Gerresheimer, 2019) 
Cash transferred 
161 €mio
recorded as "other 
non-current Liability" 
74 €mio
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As for the revenue allocation per division, the “Plastic & Devices” business contributed with 
55% (752 EURm) to the total revenue generation in 2018 and developed positively from 2014 
onwards at a CAGR of 5,8%. This positive development is mainly due to the acquisition and 
inclusion of “Centor” in September 2015 (American subsidiary). The “Primary Packaging” unit 
reported sales of 605 EURm in 2018 which represents a share of 44% based on overall revenues. 
Its historical development has been slightly negative at a CAGR of -0,7%. Lastly, the newly 
acquired division “Advanced Technologies” contributed with 1% (13 EURm) to overall 
revenues.  
€m 2014A 2015A 2016A 2017A 2018A  CAGR 
 Plastic & Devices  599 645 765 757 751 
 5,84% 
 y-y-growth in %  
 7,8% 18,6% -1,1% -0,8%   
 Primary Packaging Glass  622 651 611 592 605 
 -0,69% 
 y-y-growth in %  
 4,6% -6,2% -3,0% 2,2%   
Life Science Research5 87       
 y-y-growth in %         
 Advanced Technologies       13 
  
 y-y-growth in %  
       
 Intercompany Sales  (18) (13) (1) (1) (2) 
  
 Total  1.290 1.283 1.376 1.348 1.368 
 1,47% 
 y-y-growth in %  
 -1% 7%6 -2% 1%   
Table-5: Revenues by division 2014-2018 (Gerresheimer, 2019) 
4.1.3.3 Cost Structure 
According to Gerresheimer, the cost of sales (COGS) include “the cost of goods manufactured 
and sold and the purchase cost of merchandise”. SG&A expenses consist of the “personnel and 
non-personnel expense for administrative functions as well as for the sales and distribution 
organization”. D&A and Impairment charges are shared between COGS and SG&A-expenses.  
Gerresheimer is an energy-intense business and relies on commodities, particularly on oil for 
the glass- and plastic production. Gerresheimer agreed on certain “price variation clauses” in 
some contracts that allow them to pass on changes in commodities to customers. Due to strong 
management-skills, Gerresheimer managed to delink itself from fluctuations in commodity 
prices and to keep a stable COGS-Margin of 70% on average. The increase of COGS in 2016 
was mainly due to the acquisition and inclusion of “Centor”. Detailed costs attributable to 
Sensile cannot be replicated. However, the impact is not material due to Sensile’s small size. 
  
                                                          
5 Sold as of October 31, 2016: divisions revenue and earnings were deducted from 2015 and 2016 results 
6 High revenue increases due to the inclusion “Centor” in the consolidated financials 
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€m 2014A 2015A 2016A 2017A 2018A   CAGR 
 COGS  (934) (909) (944) (934) (968)  0,89% 
 thereof D&A 83 84 84 85 99    
 y-y-growth in %  
 -3% 4% -1% 4%   
 % sales  72% 71% 69% 69% 71%   
 Gross Profit  356 374 432 414 400  2,96% 
 y-y-growth in %  
 5% 16% -4% -3%    
 Gross Margin  28% 29% 31% 31% 29%   
 SG&A  (222) (243) (255) (256) (259)  3,96% 
 Thereof D&A 22 40 43 40 38   
 y-y-growth in %  
 9% 5% 0% 2%   
 % sales  17% 19% 19% 19% 19%   
Table-6: Historical cost development (Gerresheimer, 2019) 
4.1.3.4 Profitability 
Table-7 provides profitability measurements and illustrates the impact of the Sensile-
Acquisition. Sensile performed negatively, which leads to an improvement in net income, when 
not including it. Overall, EBITDA- and EBIT-margins are still in line with historical values and 
only changed marginally after the consolidation.  
 




 EBITDA  235   306   307   306   277   4,16% 3   274   3,89% 
 y-y-growth in %   30,4% 0,1% -0,3% -9,5%   -10,5%  
 EBITDA-Margin  18,2% 23,9% 22,3% 22,7% 20,2%   20,2%  
 EBIT  130   182   180   181   139   1,79% (7)  147   3,13% 
 y-y-growth in %   40,1% -0,8% 0,2% -22,9%    -18,7%  
 EBIT-Margin  10,1% 14,2% 13,1% 13,4% 10,2%   10,8%  
 Net Income   73   113   168   103   131   15,83% (7)  138   17,36% 
 y-y-growth in %   54,6% 49,3% -38,7% 27,2%    34,1%  
 NI-Margin  5,6% 8,8% 12,2% 7,6% 9,6%   10,2%  
Table-7: Profitability figures as reported (Gerresheimer, 2019) 
 
The company made use of tax-loss carry forwards of 24 EURm in the last year leading to a 
comparatively high net income. Otherwise, the tax rate would have been 27,6% which would 
have resulted in a hypothetical net income of 77,6 EURm (6% of sales). An overview of the 




For valuation purposes, EBITDA and EBIT are usually adjusted for non-recurring items in 
order to provide a normalized view of the profitability of a company. (Rosenbaum et al., 2009) 
By doing so, one arrives at margins that are slightly lower, but more realistic given the M&A-
activities in the past that led to several one time-effects. Examples of the biggest line-items are 
“one-off-income/expenses”, that are directly linked to the “Centor-acquisition” and 
significantly influenced operating results. 
 
The exclusion of non-recurring items results in lower margins as illustrated below: 
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4.1.3.5 D&A and Capex 
Important items in Gerresheimer´s financials are D&A and capex. In the analyzed period, 
depreciation was on average 14,4% of PPE, while amortization amounted to 3,3% of 
Intangibles. D&A refer to PPE/Intangibles as of the end of the period. By excluding Sensile-
Medical, amortization decreased slightly, but depreciation stayed constant as Sensile is mainly 
technology-driven and no material tangible assets were identified.  
Capex decreased steady since 2014 and amounted to 9,0% of total sales in the same period, or 
8,9% excluding Sensile. Most of the investments, are allocable to tangible assets. 
Historically, the company depreciated (617,39 EURm) slightly more than re-invested (599,0 
EURm) which equals a percentage-relationship of D&A and capex of 103,6%. the focus of last 
year’s capex was the expansion of the inhaler production in the US and Czech Republic and the 
general production plant modernization/automation in Germany and US.  
 




Amortization 19 42 41 36 45   10 34  
% Intangibles 3,5% 3,4% 3,4% 3,3% 3,2%  3,3%  3,2% 3,3% 
Depreciation 86 82 85 89 92    92  
% PPE 14,8% 13,6% 14,0% 14,8% 14,9%  14,4%  14,9% 14,4% 
Total D&A 105 124 126 125 137    127  
% sales 8,1% 9,7% 9,2% 9,3% 10,0%  9,3%  9,3% 9,1% 
           
Capex (tangible) 123 122 109 99 110   0,45 109  
% sales 9,5% 9,5% 7,9% 7,3% 8,0%  8,5%  8,0% 8,5% 
Capex (Intangible) 3 4 4 20 5      
% sales 0,3% 0,3% 0,3% 1,5% 0,4%  0,5%    
Total Capex 126 126 113 119 115    109  
% sales 9,8% 9,8% 8,2% 8,8% 8,4%  9,0%  8,0% 8,9% 
Table-8: Overview D&A and Capex; 2014-2018 (Gerresheimer, 2019) 
4.1.3.6 Financial Position  
As illustrated in Table-9, the financial position developed stable despite several M&A-
activities. The figures are based on book values and refer to “Post-Sensile-Acquisition” as the 
data presented by Gerresheimer does not allow a more detailed breakdown. Net debt was 






€m (book values) 2014A 2015A 2016A 2017A 2018A   CAGR 
 Net Debt  419 903 813 881 942  22,48% 
 Net Debt / EBITDA  1,8x 3,0x 2,7x 2,9x 3,4x  17,58% 
 Fin. Debt / Assets   0,3x 0,4x 0,4x 0,4x 0,4x  4,50% 
 Fin. Debt / Equity   0,9x 1,6x 1,2x 1,3x 1,1x  5,20% 
 EBIT interest coverage ratio  1,1x 1,0x 1,0x 1,0x 1,2x  1,99% 
 
     
  
 Cash  73 68 94 118 80  2,21% 
 Cur. Assets / Cur. Liabilities  1,1x 0,8x 1,0x 1,1x 0,7x  -9,34% 
        
Table-9: Financial position 2014-2018 (Gerresheimer, 2019) 
The financial debt consists mainly of promissory- and syndicated loans as shown in Figure-17. 
Compared to its peers, Gerresheimer is slightly more leveraged. The peer group Net 
Debt/EBITDA ratio (LTM-median) is 1,8x. 
 
4.1.4 Gerresheimer’s strategy moving forward 
The new CEO, Dietmar Siemssen, switched to “attacking-mode” according to Februaries 
earnings call and focuses on tackling opportunities arising from the latest megatrends. 
Siemssen seems to have a structured idea on how to improve operational performance, 
productivity and profitability. In the past, Gerresheimer struggled in providing promising 
growth and was engaged in organizing the business and managing its acquisitions. According 
to Management, the company does not plan any further M&A-activities and is expecting 
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Figure-17: Financial Debt (Gerresheimer, 2019) 
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Siemssen wants to further focus on quality and puts a lot of trust on Sensile-Medical. Given the 
high variable consideration of the purchase price, the success of the division will be highly 




5 Valuation  
5.1 Valuation approach 
The Valuation of Gerresheimer will be conducted based on the 30.11.2018. (end of the fiscal 
year) If available, all information will be sourced as of this date.  
For the purpose of this thesis, the DCF- and the trading multiples-approach have been chosen 
as most applicable. The enterprise value will be determined using the sum-of-the-parts method, 
as illustrated in Figure-18. Thus, the core-units P&D and PPG will be projected on a 
consolidated basis, while Atech will be excluded from the accounts and valued based on its fair 
market value. The newly generated unit will be covered in chapter 5.2, whereas chapters 5.3 
and subsequent refer to the core-business.  
The output will be benchmarked using a set of trading multiples derived from the financials of 











5.2 Advanced Technologies  
Due to the lack of historical information, it is not possible to reasonably forecast Atech´s 
financials. Hence, the purchase price is assumed to be measured at fair value and will be added 







Enterprise Value will be determined using a DCF-model 
Advanced 
Technologies (Atech) 
EV: 336 EURm 
PPG P&D 
Gerresheimer´s total Enterprise Value 
As a sum of PPG, P&D and Atech 
Figure-18: Valuation approach 
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The purchase price (fair value) of Sensile/Atech amounts to 335,754 EURk, of which 175 
EURm are dependent on milestones throughout the next 3 years. The purchase price could 
mainly be allocated to R&D, technology, patents, contracts and other intellectual property. No 
material tangibles were identified, making the division solely technology driven.  
Through the newly generated division, Gerresheimer’s plans to get access to more lucrative 
customer relationships and to move up the “drug value chain” – especially in the Parkinson-
pumps-business; a market that is roughly valued at 3,4 USDbn according to Hock & Aufhäuser 
(2019).  
5.3 Financial Forecast – Core Business 
In the following, Gerresheimer’s core business financials are projected based on the data as of 
30.11.2018. The forecast is modeled from 2019 to 2023, including terminal value adjustments. 
The corresponding financial statements (excluding Sensile/Atech) are projected in appendix-8 
to-10. The underlying data for the projection period is taken from the sources as quoted in 
Chapter 3-4. 
5.3.1 Revenues 
Revenues are projected separately based on division specific drivers and expectations. Figure-
19 provides a summary of the developments as discussed in Chapter 3.2.1.  
  
Figure-19: Drivers: approximate CAGR 2019-2023 
Valuation 
31 
A weighted average of the above trends is applied and afterwards adjusted for different projects 
and expectations. It is assumed that intercompany sales are zero in the explicit period as there 
is no indication to assume differently and as intercompany sales were negligible in 2018 (0,1% 
of total revenues).  
In 2018, sales were assumed to grow by 4-5% according to Management´s mid-term guidance 
for the fiscal-year 2018. This was missed by 2,5-3,5% compared to a reported CAGR of 1,5% 







5.3.1.1 Plastic & Devices  
The Plastic & Devices division is Gerresheimer’s biggest unit in terms of revenue generation. 
Sales are expected to grow less than historical rates due to non-organic growth in 2015/2016 


















2014 2015 2016 2017 2018 2019F 2020F 2021F 2022F 2023F







Figure-21: Revenue development P&D 
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Figure-20: Revenues development – core business 
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It is assumed that revenues are tied with pharma growth of 2,2% and generic-/biosimilar 
products growth of 3,5% as well as other megatrends. Furthermore, given Gerresheimer’s 
recent cooperation with Sanofi, who exchanged its animal health business with Boehringer-
Ingelheim’s consumer healthcare business (self-medication), orders from Sanofi for insulin-
products in the self-medication area are expected to increase.  
Additionally, new inhalation contracts worth 30,0 EURm per year are taken into consideration, 
as stated in the Management´s presentation in the earnings call 2019. High capex in 2019 and 
2020 will allow to meet the increased demand and is modeled to additionally pay off from 2022 
onwards. (appendix-6a) provides more information regarding the sales evolution)  
€m 2019F 2020F 2021F 2022F 2023F 
Market Growth / Megatrends 773 795 819 844 869 
Plus: New inhaler projects 30 30 30 32 32 
Less: Expiration of projects (28) (28) (28) (28) (28) 
Net Market outperformance 2 2 2 4 4 
Total Revenue 777 799 823 852 877 
 3,4% 2,9% 2,9% 3,5% 3,0% 
Table-10: Revenue derivation P&D 
Although, Gerresheimer presented promising projects in its 2019 earnings call, author´s 
forecast is on the lower end of management expectations that projected sales to be up to 4-7% 
from 2018 onwards. This is mainly due to the expiration of projects with Pfizer and the trend 
towards non-plastic products. In line with consensus (ranging between 3% and 5%), 
Management expectations were considered as being too optimistic and more conservative 
models are presumed to be more accurate.  
5.3.1.2 Primary Packaging Glass 





























Figure-22: Revenue development PPG 
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The underlying assumption of the revenue growth in the glass business is the mission of the 
new CEO to bring the glass business “back on track” by focusing on “growth and excellence”.  
Like for the Plastic division, first the drivers are projected and then company specific 
adjustments are pursued. The Glass unit is following the pharma growth (2,2%) as well as the 
generics- and biosimilar growth. The last two are expected to impact the glass business slightly 
less (2,6% and 2,0% respectively) as they are less common for liquid drugs. Market growth is 
exceeding historical growth in the explicit period, mainly due to the confidence of the new CEO 
in the glass business and the possible decrease in demand in the plastic sector. (A detailed 
revenue forecast is provided in appendix-6b) 
Gerresheimer is a main supplier for heparin pre-fillable syringes and gained new customers that 
add additional 20,0 EURm of revenue per year. The heparin projects are Gerresheimer’s most 
promising ones and will maintain relatively strong in the upcoming years.  
Glass business’s sales are below management assumptions mainly due to the shutdown of two 
of Pfizer’s facilities in India as a reaction of falling demand in the injectable penicillin business. 
(Mathias, 2019) According to own research based on historical values, the corresponding 
impact on the unit´s sales is measured at 18,0 EURm. Overall, the unit is projected to grow 
2,6% per year.  
€m 2019F 2020F 2021F 2022F 2023F 
 Revenues from market growth  620 635 652 669 687 
Plus: New syringes contracts 20 20 20 20 20 
Less: Pfizer and other contract losses (18) (18) (18) (18) (18) 
Net Market outperformance 2 2 2 2 2 
Total Revenue 624 639 656 673 691 
 3,1% 2,5% 2,6% 2,6% 2,7% 
Table-11: Revenue derivation PPG 
5.3.2 Cost Structure 
Gerresheimer does not report detailed information about their cost structure and values cannot 
be reasonably broken down to its divisions. According to Management, less information is 
provided as the cost structure represents their competitive advantage. Therefore, function costs 
follow a stable gross margin of 29,6%, as illustrated in Figure-24. This is on the rather higher 
end of historical values (chapter 4.1.3.3) due to automation and modernization improvements 
in Gerresheimer’s facilities.  
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An overview of the cost-development, as a percentage of sales, is shown in Figure-23. SG&A 
are following stable historical values of 18,5% of sales, except for 2019 and 2020 where it 
increases by 0,3%. Non-recurring items, as for example income/losses from derecognition of 
liabilities or from the disposal of assets and similar items as stated in appendix-7, are not 
included in the forecast. They are not likely to persist continuously, and no historical pattern 
could be discovered. Furthermore, exchange gains were 0,03% of sales on average over the last 
5 years and will not be projected due to its low impact and the lack of information. Similarly, 
R&D (0,19% of sales - historical average) is considered as not relevant, as Gerresheimer is not 
active in R&D since the sale of its research-department in 2016.  
Any potential “other operating income/expenses” are expected to offset each other and have 
thus no impact on the valuation. Restructuring expenses, that fall under the IFRS (IAS 37) 
regulations, are considered as recurring. Given the non-organic growth and capex increases in 


























2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Revenue - Gross profit development
 Revenue Gross Profit Gross Margin
72,4% 70,9% 68,6% 69,3% 70,7% 70,4% 70,4% 70,4% 70,4% 70,4%
17,2% 18,9% 18,6% 19,0% 19,0% 18,8% 18,8% 18,5% 18,5% 18,5%
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Cost structure development (as a % of sales)
Revenue Cogs SG&A Restructuring Expenses
Figure-24: Relationship between revenues and gross profit 





expenses in that regard. Therefore, restructuring expenses are included in the model and 
expected to be 0,8% (in line with 2018´s values) of sales in 2019 and 2020 and 0,4% (historical 
average) in the following years.  










Below, EBIT and EBITDA are projected, excluding Sensile-Medical: 
€m 14A 15A 16A 17A 18A 19F 20F 21F 22F 23F TV 
EBITDA 235 306 307 306 274 269 279 294 300 307 314 
Margin 18,2% 23,9% 22,3% 22,7% 20,2% 19,2% 19,5% 20,0% 19,7% 19,7% 19,7% 
EBIT 130 182 180 181 147 139 143 158 162 167 170 
Margin 10,1% 14,2% 13,1% 13,4% 10,8% 10,0% 10,0% 10,7% 10,7% 10,7% 10,7% 
Table-12: EBIT(DA) development 
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EBIT is modelled based on the forecasts of revenues and costs in line with historical figures. 
Given the competitiveness of the industry, historical margins (EBITDA-margin along with 
peers average is shown in Figure-26) have been in line with its peers, which is assumed to retain 
in the future in order to not be significantly more/less profitable than its environment.  
 
As illustrated below in Figure-27, EBIT margin will decrease marginally in 2019 and 2020 due 
to slight increases of SG&A and restructuring expenses that come in line with Gerresheimer´s 
growth path. From 2021 onwards, margins will go back to normal levels. Lastly, EBITDA is 
calculated by adding back D&A. Compared to reported historical values, margins are slightly 
lower in the projected period, but in line with historical adjusted values. This is due to several 
one-times-effects in the past, especially in the light of disposals of business units, that positively 
affected margins and are not included in the forecast. EBITDA-margin in TV matches with last 
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EBITDA Margin - peer group range
 average
 Gerresheimer
Figure-27: adjusted EBIT(DA) and projection 
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5.3.4 Capital expenditures and D&A 
As suggested by Koller et al., (2015), PPE should be a function of revenues, as PPE/revenue-
ratios tend to be quite stable over long periods. In Gerresheimer´s case, PPE increases in 2019 
and 2020, as predicted by the management and follows a stable ratio of 49% afterwards. 
Similarly, intangibles are linked to revenues, but decrease throughout the explicit period as no 
more non-organic activities are planned, that would allow the identification of intangibles in 
the course of a purchase price allocation. Furthermore, as Gerresheimer´s core-business is 
tangible-focused, intangibles are expected to decrease by 3% per year.  
D&A is following a function of PPE/Intangibles at the end of the year as illustrated in Figure-
29. Particularly, depreciation is modeled as 15,3% of PPE in line with historical values and 
management guidance. Management presented several investment projects that justify the 
growth in PPE, accompanied by deprecation increases. 
Amortization follows a 2,4%-margin of intangibles constantly and is lower than historical 
values, due to impairment losses following the acquisition of “Centor” in 2015 that biased the 
financials.  
Figure-28: PPE/Intangibles development 
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In order to complete the PPE/Intangibles computation, one has to compute investments; capex 
represents the difference between the asset´s value at the beginning of the period, less current 
years D&A and asset´s value at the end of the period, as calculated using a function of sales. 
The computation is in line with Management’s estimation of capex being between 8-12% of 
sales, where the higher end should be at the beginning of the explicit period. Detailed figures 
of D&A/Capex- and PPE/Intangibles-computation is provided in appendix-14 &-15. 
Finally, for TV purposes, it is assumed that D&A and capex converge over time and company’s 
asset base will stay constant in perpetuity. Thus, they are neither growing nor decreasing faster 
than depreciation.  
3,5% 3,4% 3,4% 3,3% 3,2%
2,4% 2,4% 2,4% 2,4% 2,4%
14,8%
13,6% 14,0%
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5.3.5 Net Working Capital 
The change in working capital is computed by deducting non-cash operating current assets from 
operating current liabilities, taking into consideration the portion of operating long-term assets 
and liabilities.  
Accounts receivable, inventory and accounts payable are projected based on days sales 
outstanding (DSO), days inventory held (DIH) and days payable outstanding (DPO) as an 
average of the last 5-years (illustrated in Figure-31).  
 
Deferred tax assets/liabilities are assumed to grow with operations (revenues) in line with 
historical values. All other NWC-items are projected as a percentage of sales in line with 
historical levels or stay constant. Change in NWC in the TV is following the historical net 
change as percentage of revenue. Particularly, the average NWC-change from 2014-2023 
(excluding 2015), was 0,5%, which is multiplied by sales and the TV growth rate.  
The cash conversion cycle indicates that less cash is tied up from 2017 onwards compared to 
the past. As it cannot be predicted if this trend is sustainable, the whole 5-years’ cycle was 
captured when calculating DSO, DIH and DPO. All underlying WC assumptions are illustrated 
in appendix-13. 
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2014A 2015A 2016A 2017A 2018A
Cash Conversion Cycle 
DSO DIH  DPO  CCC
Figure-31: Cash conversion cycle in days 
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€m 14A 15A 16A 17A 18A 19F 20F 21F 22F 23F 
A/R 208 219 232 243 264 246 253 260 268 275 
Inventory 194 186 155 148 171 180 184 190 195 201 
Prepaid Expenses 4 4 5 3 5 4 4 5 5 5 
Income Tax 
Receivable 
5 5 8 4 7 5 5 5 6 6 
Other receivables 24 29 21 19 24 24 23 22 21 20 
Deferred Tax 
Assets 
7 8 14 11 12 11 11 11 12 12 
           
Deferred Tax 
Liabilities 
(33) (147) (158) (144) (92) (120) (123) (126) (130) (134) 
Income Tax 
Liabilities 
(22) (55) (25) (9) (5) (7) (8) (8) (8) (8) 
Other provisions7 (62) (71) (61) (45) (55) (55) (55) (55) (55) (55) 
A/P (125) (161) (157) (176) (205) (173) (178) (183) (188) (194) 
Deferred Revenue (44) (31) (30) (28) (35) (35) (36) (37) (38) (39) 
NWC 158 (14) 4 26 92 79 81 83 86 89 
∆ in NWC (44) (172) 18 22 66 (12,6) 2,1 2,3 2,7 2,7 
           
∆ in NWC 
as % of Revenue 
-3,4% -13,8% 1,6% 1,6% 4,8% -0,7% 0,1% 0,2% 0,2% 0,2% 
Mean ∆ in NWC          0,5% 
Table-13: Change in NWC 
The change in NWC of -172 EURm in 2015 that led to a boost in FCFF, was mainly due to 
increases in deferred tax liabilities and accounts payable following the acquisition of “Centor”. 
5.3.6 FCFF 
Based on the projected financials, the FCFF for the P&D and PPG units is illustrated below. A 
reformulated core FCF-derivation is provided in appendix-11. 
€m 2014A 2015A 2016A 2017A 2018A 2019E 2020E 2021E 2022F 2023F TV 
EBIT 130 182 180 181 147 139 143 158 162 167 170 
less: Taxes (35) (54) (52) (53) 33** (38) (39) (43) (45) (46) (47) 
EBIAT 95 128 128 128 180 101 104 114 117 121 123 
Plus: D&A 105 124 126 125 127 129 136 137 138 140 144 
Less: 
CAPEX 
(127) (126) (113) (119) (114) (180) (170) (128) (129) (144) (144) 
Less: ∆ in 
NWC 
44,2 172,0* (17,9) (22,1) (66,0) 12,6 (2,1) (2,3) (2,7) (2,7) (0,2) 
FCFF 118 299 123 112 126 63 68 121 123 114 123 
Table-14: FCFF derivation core business  
*boost in FCF following the acquisition of “Centor”  
**use of tax-loss carry forward 
                                                          
7 Mainly personnel obligations and warranties 
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5.3.7 Terminal Value growth rate 
Gerresheimer´s growth rate in perpetuity is assumed to be 2,25% following the formula in 
Figure-32. The value is derived by firstly analyzing the nominal GDP growth of the German 
economy (appendix-29 provides the computation). German`s economy was chosen as 
Gerresheimer is headquartered in Germany and as its GDP growth represents a good guidance 
of a developed environment. It is expected that emerging countries with a temporary high 
nominal GDP growth, will converge with German´s growth in perpetuity making their current 
status as a “fast-growing-economy” not sustainable.  
Secondly, given the competitiveness of the industry, it is assumed that Gerresheimer´s TV 
growth rate should be in line with its peers. For that purpose, an implied TV growth rate of 
1,9% based on an Exit-EBITDA-Multiple of 11x (peer group median-2019) is applied.  
The third component is based on Gerresheimer´s expected long-term growth of 1,5% which is 
in line with historical performance and consensus estimates from equity reports. Finally, the 
average of the components was taken in order to arrive at a conservative TV growth rate of 
2,3%. This matches with the estimated pharma long-term growth of 2,2% according to IQVIA, 
as well as the long-term inflation rate for Germany (2,2%, according to IMF). Appendix-30 
provides sensitivities and hypothetical share price ranges. 
 
5.4 Cost of Capital 
The WACC, and its components, are presented “post-Sensile-acquisition” in order to reflect the 
undistorted risks and capital structure as of the valuation date. This assumption is supported by 
the low impact of the newly generated division and the lack of detailed public information in 
that regard.  
5.4.1 Capital Structure 
According to Gerresheimer, the current capital structure is in the best interest of its shareholders 













Figure-32: Terminal value growth rate derivation 
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structure at market value (net debt/market cap) as per 30.11.2018 is applied in the WACC-
computation. The market value of equity is obtained by multiplying the share price as of 
30.11.2018 with its shares outstanding. Market value of debt is computed by discounting future 
interest expenses and future debt-repayments to the valuation date using the cost of debt at 
market value as explained in chapter 5.4.6. 




 Less: Cash  €m (80) 
 Net Debt   €m 923 
    
 Share price  € 63 
 Times: Shares outstanding  31,4 m 
 Market Cap  €m 1.975 
Table-15: Capital Structure at market values as per 30.11.2018 
Gerresheimer plans to keep a rather stable payout-ratio for its shares. Historically, the dividends 
per share were 1,0€ on average (2014-2018) and are planned to stay constant at 1,1€ for the 
projected period. This represents a dividend yield of 1,4%. (appendix-12) 
5.4.2 Beta 
The levered beta is computed by regressing the MSCI World Index against the 5-years weekly 
returns of every single peer. The MSCI was chosen as it represents a global market-cap-
weighted stock index of more than 1600 companies. Given that the beta is regressed on a 5y 
basis, the author made sure that a whole business cycle is captured and that impacts from 2008’s 
financial crisis are excluded. 
Secondly, the raw betas are adjusted according to Blume as stated in chapter 2.2.2.1. 
Thirdly, every adjusted levered beta is unlevered using the capital structure of the individual 
peer company. It is assumed that the peers have already achieved their target capital structure. 
It is further assumed, that the market value of debt of the peers equals the book value. 
Companies with an R-square lower than 0,1 have been considered as not significant. In a next 
step, the weighted average is taken to arrive at a beta of 0,83. Another possibility would be to 
take the raw-betas from sources as Reuters. However, as Reuters does not provide values as of 
the valuation date, the author considers the values derived by the regression analysis to be more 
accurate as of 30.11.2018. For comparison purposes, betas pulled from Reuters in the period of 
April to May, result in a beta of 0,85 which is in line with own calculations. The possible impact 
on the share price is low. 
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Finally, the unlevered beta is levered back using Gerresheimer`s capital structure at market 
value and the effective tax rate. An overview of the beta-derivation is attached in appendix-21.  
5.4.3 Effective Tax Rate  
The effective tax rate of 27,6% is obtained based on the annual report 2018. This is in line with 
2019`s first quarter rate of 27,9%. Due to changes in US-tax law in 2017 and further changes 
coming in France in 2019, the effective tax-rate is difficult to measure, and historical rates 
before 2018 only provide a limited insight. Therefore, it will be subject to a sensitivity analysis. 
5.4.4 Cost of Equity  
As a risk-free rate, a 10y German government bond is applied as of valuation date. Regarding 
the computation of the equity-risk-premium, literature review showed (chapter 2.2.2) that one 
possible approach would be to derive the geometric mean of the total returns on the MDAX 
over a long period (to cover bullish and bearish markets). However, as this data is hardly 
available, a MRP of 7% in line with theory and recommendations was applied. 
 
Figure-33: German government bond 
 
By applying the CAPM, one arrives at a Cost of Equity of 8,1% as illustrated in Figure-34. 
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As mentioned in chapter 2.2.2, no country risk premium will be added, as Gerresheimer is 
considered as being diversified, given its globally well spread facilities and sales-generation. 
5.4.5 Cost of Debt 
As Gerresheimer does not have traded bonds outstanding, the cost of debt is computed by using 
a synthetic rating based on the coverage ratio and the analogous credit spread. The coverage 
ratio (EBIT/interest expenses) equals 5,8x in Gerresheimer´s case which corresponds to an “A-
rating” according to Damodaran´s table (appendix-32).  
In a next step, an A-rated corporate bond (EUR Industrial; average of 45 euro-area rated 
corporate A-bonds) was sourced from Capital IQ as of 30.11.2018. (as illustrated in Figure-35 
and in more details in appendix-19) Its maturity matches the average of the remaining term of 
the debt outstanding. Finally, as the credit spread represents the value of the corporate bond 
over the risk-free rate, a spread of 0,90% (4 years maturity) is derived. By adding the 
corresponding risk-free rate of -0,40%, and by applying the tax-shield, one derives at a cost of 
debt of 0,33%. 
 
Figure-36: Cost of Debt  
 
  
Cost of Debt after Tax 
0,3% 
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Figure-35: Corporate Bond 
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5.4.6 Market Value of Debt 
To determine the market value of debt, first the interest payments per year are computed and 
discounted to the valuation date using the cost of debt of 0,3%. Similarly, the debt repayments 
are discounted and added to the present value of the interest payments to derive at a total of 
1 EURbn. This includes 8 EURm of financial leases, of with the market value equals the book 
value as it is presented at fair value at the end of the fiscal year in the annual report.  














170 2015 2020 2 1,0% 1,7 172 
20 2015 2020 2 0,8% 0,2 20 
160 2015 2022 4 1,4% 2,3 167 
50 2015 2022 4 1,0% 0,5 51 
26 2015 2025 7 2,0% 0,5 29 
90 2017 2022 4 0,8% 0,7 92 
6 2017 2022 4 0,6% 0,0 6 
105 2017 2024 6 1,3% 1,3 110 
5 2017 2024 6 0,8% 0,0 5 















189 2014 2019 1 5,3% 10,0 197 
12 2014 2019 1 2,1% 0,3 13 
80 2014 2019 1 0,8% 0,6 80 
0,05 2014 2019 1 26,3% 0,0 0 
3 2014 2019 1 9,3% 0,3 3 
Table-16: Market value of debt 
5.4.7 WACC 
By applying the individual components, the author arrives at a base-case WACC of 5,6%. A 
full derivation is provided in the appendix-18.  
 
  













5.5 Sum of the parts DCF 
Based on the FCF one can perform the DCF-valuation in order to compute the share price. A 
complete set of the DCF valuation is provided in Appendix-33. 
 30.11.2018 2019F 2020F 2021F 2022F 2023F  TV 
FCF  63,4 68,2 120,6 123,1 114,4  123,2 
WACC 5,62%        
TV growth 2,25%        
Mid-year convention  0,5 1,5 2,5 3,5 4,5  5,5 
PV factor  0,97 0,92 0,87 0,83 0,78  23,23 
PV of FCF  61,7 62,9 105,2 101,7 89,5  2.861,5 
Table-17: PV of Free-cash-flow 
The enterprise value equals the sum of the individual present values of the free cash flows 
including the terminal value. The TV is obtained by applying the perpetuity-growth-formula on 
the FCF of the “terminal-value year”. A mid-year convention is applied, as Gerresheimer´s cash 
flows are received throughout the year rather than at year-end. This results in a slightly higher 
valuation since the FCFs are received sooner.  
The purchase price of Sensile (at fair value) is added to the sotp enterprise value to arrive at 
Gerresheimer´s total firm value of 3,6 EURbn. 
Enterprise Value  Equity Value 
 Cumulative PV of FCF   420,9   Enterprise Value  3.617,1 
 Terminal Value   2.861,5   Plus: Cash  79,8 
 in % of (core) Enterprise Value   87,2%   Less: Debt  (1.002,8) 
  
 
  Less: NCI  (76,2) 
 Enterprise Value PPG and P&D   3.282,4   Less: Pensions and others (184) 
 Enterprise Value Adv. Technologies     334,8   Adjustments to EV  (1.182,9) 
  3.617,1   Equity Value  2.434,2 
     Shares Outstanding (m) 31,4 
Implied Exit-Multiple  12x    
implied perpetuity growth (Peer Exit-Multiple)  1,9%   Share Price (30.11.2018) 78 
Table-18: Enterprise – Equity Value 
As illustrated Figure-38, in excess cash, market value of debt, non-controlling interests as well 
as other items as illustrated above, are deducted/added-back from the enterprise value to arrive 
at the equity value. The market value of non-controlling interests are computed using an 
industry P/BV-multiple of 4,36x according to Damodaran (2019).  
 





Afterwards, the equity value is divided by the number of outstanding shares (31,4m) to obtain 
the share price of €78 (outperform). This represents an upside potential of 15% compared to 
the share price of €69 as per 8th of May, 2019. Compared to the price as of valuation date (€63), 
the target price represents an upside-potential of 24%.  
In conjunction with the perpetuity growth model, an Exit-multiple based on EBTIDA of the 
terminal year was computed. Gerresheimer´s implied Exit-multiple is 12x, whereas forward 

























Equity - Enterprise Value Bridge






5.6 Sensitivity Analysis 
The “Base-Case” (target price) represents the main scenario applied 
in this valuation using the inputs as described in the previous 
chapters. 
The “Blue-Sky” valuation is arrived by applying an underlying 
growth of 5% per year, assuming strong contribution from new 
products. 
The “Grey-Sky” scenario is assuming a revenue growth of 1% due 
to the lack of contribution from new products and a poor pharma 
market situation. 
The “current price” is based on the share price as per 08.05.2019. 
Other sensitivity analyses are based on variations of the WACC and the terminal value growth 
rate as illustrated in Table-19: 
 
 Enterprise Value  Share price 
 TV  TV 






4,6% 4.388 4.677 5.016 5.417 5.899  4,6% 102 111 122 135 150 
5,1% 3.763 3.965 4.194 4.459 4.766  5,1% 82 89 96 104 114 
5,6% 3.304 3.452 €3.617 3.803 4.015  5,6% 68 72 €78 83 90 
6,1% 2.952 3.065 3.189 3.327 3.481  6,1% 56 60 64 68 73 
6,6% 2.675 2.763 2.859 2.965 3.081  6,6% 48 50 53 57 60 
              
 Implied EV/EBITDA Exit-Multiple  Implied EV/EBTIDA Y1 
 TV  TV 






4,6% 15 16 17 19 20 
 4,6% 16 17 19 20 22 
5,1% 12 13 14 15 16 
 5,1% 14 15 16 17 18 
5,6% 11 11 12,0x 13 14 
 5,6% 12 13 13,5x 14 15 
6,1% 9 10 10 11 12 
 6,1% 11 11 12 12 13 
6,6% 9 9 9 10 10 
 6,6% 10 10 11 11 11 













Additionally, Table-20 shows further share price sensitivities by varying critical input factors. 
As expected, the assumptions made regarding the tax-rate and mid-year convention are rather 
insignificant compared to changes in EBIT-margin, Beta or Cogs.  
   
   
 Cogs   +-1,5% 63 78 94 
 EBIT-margin  +-1,5% 64 78 82 
 Tax-rate   +-2% 77 78 80 
 Mid-year convention  N/Y 76 78 78 
 Beta   +-0,1 61 78 103 
Table-20: Additional sensitivities  
Although, changes in gross-margins are unlikely given their historical consistency, a variation 
still shows that, for example, increases in commodity prices that cannot be passed on to the 
customer, impact the share price.  
Besides, a Monte Carlo analysis is performed by varying the inputs as described in Table-20 
including revenue growth (+-7%) and excluding mid-year discounting. The results support the 
“buy” recommendation. The mean of 10000 trials is €75. The corresponding histogram to 
Figure-40 is provided in appendix-28. 
 
  












 Buy: X >  74
 Hold: 64 < X > 74
 Sell: X < 64
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5.6.1 Advanced Technologies 
The author has limited insights into the acquisition details of Sensile/Atech and the variable-
consideration of the purchase price. In this thesis, the enterprise value equals the maximum 
purchase price and a failure of the achievement of milestones, would consequently decrease the 
enterprise value. However, the author concluded that any sensitivities regarding the fair value 
of Sensile/Atech would not directly impact the share price; a failure of payment of the variable 
compensation would, on the one hand, decrease the purchase price, but on the other hand, would 
also increase excess-cash. These two effects are assumed to off-balance in the enterprise-equity 
value bridge. 
5.7 Peer Group 
The peer group was selected, to derive the multiples for the relative valuation and to compare 
main valuation inputs. 
A “broad” peer group was created using Reuters, industry reports and Gerresheimer´s 
announcements. In a next step, companies’ financial ratios and performance indicators 
consisting of financials and efficiency measures, return on investment, leverage ratios, coverage 
ratios and credit ratings were derived. Within those criteria, most attention lies on: 
Business Description, 
EBITDA-Margin, 
Revenue CAGR (5y), 
Return On Invested Capital (ROIC), 
Debt-to-Equity (leverage ratio), 
and Coverage Ratio. 
As Gerresheimer and its multinational customers are operating globally, a geographical 
criterion is not considered for the peer group derivation. Based on the above criteria, a rating 
from 1 to 3, with 1 being “high fit”, 2 “medium fit” and 3 “no fit”, is applied. It must be 
mentioned that “Business/Product fit” is considered as being most relevant due to the specific 
nature of the industry. Hereby, a forward-looking approach is applied, meaning that peers are 
not only selected based on Gerresheimer´s current status quo, but also on how well they refer 
to Gerresheimer’s expected development over time. Particularly, megatrends and technological 
changes are considered.  
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Once the peer “passed” the business-check (rated either with a 1 or 2), a complete rating is 
conducted. Companies with less than eleven points are considered as being “most accurate”. 
Based on this approach, nine peer companies are derived. Figure-41 provides a summary, and 
appendix-26 &-27 the full peer group derivation.  
 
Figure-41: Peer-group overview 
5.8 Multiples Valuation 
EV/EBITDA and P/E multiples, both forward-looking and current, are applied in the relative 
valuation as illustrated in Table-21. A range is presented by multiplying the median-, average- 
as well as the weighted average multiple with the corresponding metric. The complete multiple-
derivation is attached in appendix-22 to-25.  
  
 EV/EBITDA  P/E 
 FY0 FY1 FY2 FY3  FY0 FY1 FY2 FY3 
 Weighted average  
 20,3 15,5 14,0 13,4  67,3 21,7 19,7 17,3 
 Average  
 13,4 12,3 11,8 10,4  34,0 22,2 22,6 18,2 
 Median  
 12,4 11,0 10,1 9,7  32,2 20,4 17,9 15,6 
  
          
  
in USDm Company Name Country Market Cap Sales EBITDA-Margin ROIC Revenue (5y Cagr) D/E Rating
1 Demant A/S DNK 8434 2126 21,59% 15,20% 9,04% 0,75 AAA
2 Ypsomed Holding AG CH 1515 489 20,50% 15,40% 13,77% 0,17 AAA
3 West Pharmaceutical Services Inc US 7475 1717 20,07% 14,60% 4,65% 0,15 AAA
4 PSB Industries SA FRA 128 316 17,95% 4,00% 8,81% 0,80 A+
5 Consort Medical PLC UK 562 428 19,86% 5,80% 26,76% 0,47 AA
6 Becton Dickinson and Co US 65789 15983 24,81% 8,41% 14,69% 1,02 BBB
7 Draegerwerk AG & Co KGaA GER 917 2982 6,09% 10,71% 1,62% 0,20 A+
8 Ansell Ltd AUS 2522 1493 15,60% 5,70% 4,20% 0,36 AA




          
SOTP (€m) 
 Implied Enterprise Value  Implied Equity Value 
 2018 2019 2020 2021  2018 2019 2020 2021 
 Metric 
 274 269 279 294  138 81 83 94 
 
          
 Weighted average  
 5.557 4.156 3.916 3.953  9.309 1.751 1.641 1.635 
 Average  
 3.659 3.298 3.291 3.057  4.695 1.788 1.882 1.716 
 Median  
 3.388 2.948 2.820 2.851  4.452 1.643 1.488 1.476 
  
          
Table-21: Relative valuation overview  
The implied Enterprise Value is derived by applying the multiple on the EBITDA of the core-
business and by adding the firm value of Atech to arrive at the total consolidated enterprise 
value. The preferred FY2 multiples range between 10x-14x and lead to an enterprise value 
range between 2,9 EURbn and 4,2 EURbn. In a next step, net debt and similar items are 
deducted from the EV, as discussed in the DCF-analysis and illustrated in Table-22, in order to 
receive the share price.  
Regarding the implied Equity Value, Atech could not be taken into consideration, as the 
corresponding financial metric (net income) is not computed on a consolidated basis. Thus, the 
presented values and share prices only reflect the equity value of the core-business.  
The share prices are illustrated in Figure-42. The lowest value refers to the median, the highest 
to the weighted mean. 




Less: Noncontrolling Interests (76)





Figure-42: implied share prices 
As mentioned, the implied equity value refers to the sotp-valuation (metric is the net income of 
PPG and P&G) and the equity of Atech is not captured. In order to still get comparable results 
of the consolidated equity value derived by multiples, consensus of the corresponding metrics 
was pulled from Reuters. (appendix-24) The ranges are presented below: 
 
Figure-43: football field (share price)  
The Y0 P/E-multiples do not give clear insights and significantly mislead the results, and might 
refer to a potential overvaluation of the peers. More attention should therefore be paid to the 
forwards, that show a more realistic picture of Gerresheimer. When comparing the PE-ratios of 
the core-business to the ratios obtained by applying consensus metrics (including Atech), one 
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significantly higher. Overall, the implied share prices obtained using the multiples, are in line 
with the intrinsic valuation. As mentioned in the literature review, forward multiples are 
preferred as they capture analyst’s expectation and often result in a better estimate. 
In conclusion, current multiples (Y0) indicate a possible undervaluation of Gerresheimer´s 
share price obtained by the DCF. However, given that no peer company is truly comparable, 
the DCF is still to be favored and multiples should be used for rough comparisons purposes 
only and for indications of share price targets. In this case, multiples support the buy sentiment 
issued in this thesis. For comparison purposes, Gerresheimer´s implied multiples, derived by 












Figure-44: Gerresheimer´s implied multiples 
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6 Investment Bank Comparison 
The results and methodologies applied in this thesis are compared with the equity report 
provided by Credit Suisse (“CS”). The investment bank report was published on February 14, 
2019 and is based on Gerresheimer´s 2018 annual report. As illustrated in Table-23, CS issued 
a “buy (outperform) recommendation”, targeting a price of 82€, compared to Gerresheimer´s 
share price of 58€ as of February 13, 2019. This recommendation was decreased by 6€ (based 
on 88€) compared to Credit Suisse´s sentiment as of September 17, 2018. 
 Credit Suisse Thesis 
Target 82€ (outperform) 78€ (outperform) 
Methodology DCF DCF – Sotp 
Explicit Period 10 years 5 years 
Revenue CAGR 5% 2,84% 




Average WACC 6,6% 5,6% 
Tax Rate 
28,0% in 2019, thereafter steady 




9,5% 8,0% on average 
CAPEX  
(% sales) 
12% in 2019 and 2020, 
8% in 2021 and 2022, thereafter steady 
decreases until reaching 7,0% in 2019 
12,9% in 2019 and 11,8% in 
2020, 8,8% (mean) from 
2021 onwards 




EV/EBIT 2020 17,8x 21,5x 
P/E 2020 14,1x 29,0x 
Table-23: Summary Investment Bank comparison 
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The main difference in the valuation lies in the nature of the methodology. While CS applied a 
consolidated DCF-model, the assumed a sum-of-the-parts approach to be more accurate. This 
method is supported given the lack of historical data for Atech. There is only a few information 
as well as projections and assumptions available and thus, the financial development could not 
be reasonably measured and projected.  
Furthermore, different financial drivers were assumed in the valuations: CS applied a 10y 
explicit period in their model with an average revenue growth of 5% and an EBIT-margin of 
13%. The long explicit period allows to decrease the dependeny on the Terminal Value, but it 
is often difficult to reasonably project over more than 5-6 years. Concerning revenue growth 
and margins, the author applied a more conservative approach given that CS`s values seem too 
high compared to historical data and industry reports. Differences also arise in the TV growth 
rate of 1,5% vs. 2,3% used in this report. Credit Suisse also applied a different tax-rate; from 
2020 onwards, the rate is substantially lower than 27,6% used by the author. Probably, CS 
estimated the decreases given the US- and France-tax changes, to be higher.  
Regarding the Cost of Capital, CS applied a periodic-specific WACC that averages at 6,6% and 
is on average around 1% higher than the rate calculated by the author. One reason that the 
difference in the share price is less significant is, that CS discounted its “rather optimistic 
assumptions” with a higher WACC.  
Differences also arise in the NWC of 9,5% in Credit Suisse´s case as opposed to 8,0% (average) 
applied in this thesis. In both valuations, changes in NWC are decreasing the FCF (use of cash). 
Capex are rather similar in both valuations because Gerresheimer announced guidance in that 
regard. After 2020, capex and D&A are back to normal values which is at around 7-9%, where 
the upper range seems more accurate given the high capital intensity of the business.  
Another difference lies in the forward PE multiple, which is significantly lower in CS`s 
valuation (14,1x) indicating a possible undervaluation of Gerresheimer. Compered to peer 
group’s 2y-forward PE-multiple that averages at 22,6x and the LTM PE-ratio of 27,6x of 
Gerresheimer according to Reuters, the value derived by CS seems not to be in line with 
comparable values.  





After the state-of-the-art valuation theory was presented, the share price of Gerresheimer AG 
was obtained by applying a sotp DCF/WACC-approach as of 30.11.2018.  
Gerresheimer´s consolidated statements were adjusted for impacts of the latest “Sensile-
Medical” acquisition, that is now the newly created business unit “Advanced Technologies”. 
The remaining business units were then valued using the DCF-approach. To reach a target share 
price of €78, the fair value (purchase price) of the Atech-division was added. The underlying 
assumptions were embossed by industry- (megatrends), and macroeconomic-developments, 
that overall, present promising conditions for Gerresheimer.  
As Gerresheimer traded at €63/share on Nov. 30, 2018, an outperform recommendation with 
an upside-potential of 24% was issued. This is in line, though rather on the lower end, with 
forward peer multiples. Despite substantial differences in revenue growth rates and WACC 
derivations, the share price is only slightly below Credit Suisse´s equity valuation.  
The equity valuation has limitations, and is, as all valuations, subject to the preferences of the 
author. Nevertheless, a Monte Carlo analysis shows that the chance of buying the stock is above 
50% which makes the author confident to issue a buy recommendation. 
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8 Appendix  
1. Porter´s five forces  
 
 
Barriers to enter – high 
In most countries, the pharma and healthcare sector, as well as its sub-industry, the medical 
equipment, supplies and distribution business, are considered as being a difficult environment 
to enter. Potential reasons might be the high capital intensity required, strict laws as well as 
regulations particularly in the light of trademarks and patents.  
Degree of Rivalry – high 
Besides Gerresheimer, the main players in the glass and plastic packaging industry are for 
example SCHOTT, Becton Dickinson or Ypsomed which are all well established in the market. 
Due to the presence of many actors, the degree of rivalry is rather high and the ability to increase 
market share is limited. In such environments, companies try to harm competitor’s profitability. 
Threat of Substitutes – moderate 
As most customers prefer traditional pharma packages, the threat of substitutes is rather low. 
Currently, there are limited substitutes available at the market that provide the same quality and 
solutions as traditional products. However, possible changes in packaging towards more 








 Barriers to Enter







Supplier Power - Low 
The supplier power in the industry can be considered as low as several well established raw-
materials (oil and gasoline) supplier own notable market shares. Furthermore, the supply of 
certain raw-materials, particularly oil and gas, overwhelms demand, which decreases the power 
of suppliers. Other energy sources as electricity is often governed and regulated by the country 
making the supplier power low. 
Buyer Power – Low 
Healthcare companies are often seen as having a high market share and thus, buyer power. 
However, according to Rickman et al. (2017) the Hirscher Herfindahl Index (“HHI”), a 
reflection of the degree of concentration in the market, lies between 500-700 points (1998-
2015), which is well below the guidelines of the Department of Justice (Antitrust Division) that 
consider a HHI of 1500 – 2500 points to be “moderately concentrated”. (DOJ, 2018) 
(Rickmann, et al., 2017) In general, in the pharma packaging industry is standard practice, to 
negotiate contracts with the buyers that allow suppliers to pass on prices (mainly due to 
increases in commodity prices). 
 
2. Swot Analysis 
Strengths Weaknesses 
• Geographic diversification, global 
representation and low dependency on a 
certain market 
• High quality products that raises 
customer´s confidence 
• Well-known brand-portfolio 
• Past declining performance of the Glass 
Business 
• Weak organic growth, growth was in the 
past mainly due to M&A 
• Gerresheimer is a contractual-
manufacturer and has limited excess to 
the more profitable R&D-business 
Opportunities Threats 
• Raising global demand for packaging 
products, especially in emerging markets 
• Technological changes, increase in 
chronic diseases and other megatrends 
as explain in Chapter 3.2.1 
• Rising public aversion against plastic 
products  
• Increasing commodity prices  
• Stricter regulations and laws  
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3. Historical Income Statement 
in Mio. € 2014 2015 2016 2017 2018  CAGR  Sensile 2018 adjusted  CAGR 
Revenues 1.290 1.283 1.375 1.348 1.368  1,47%  13 1.355  1,23% 
Cost of Sales (934) (909) (944) (934) (968)  0,89%      
Gross Profit 356 374 432 414 400  2,96%      
Selling and administration expense (222) (243) (255) (256) (259)  3,96%      
Other operating income 24 93 18 34 30  5,87%      
Other operating expenses (24) (35) (11) (9) (20)  -4,07%      
Restructuring expenses (4) (7) (2) (3) (11)  26,61%      
Share of profit/loss of associated companies 0 0 0 0 0  3,18%      
EBIT 130 182 180 181 139  1,79%  (7) 147  3,13% 
interest income 3 5 5 4 2  -8,63%      
interest expense (34) (34) (34) (35) (30)  -3,32%      
other financial expenses - (6) (4) (5) (5)        
Net finance expense (31) (35) (34) (35) (32)  1,37%      
Net income before income taxes 99 147 147 145 107  1,92%      
Income taxes (26) (43) (42) (42) 24        
Net Income from continuing operations 73 104 104 103 131  15,83%  (7) 138  17,36% 
Net income from discontinued operations - 9 64 - -        
Net Income 73 113 168 103 131  15,83%  (7) 138  17,36% 
 
As a % of sales 2014A 2015A 2016A 2017A 2018A  
Average 
14-18 
Cogs 72,4% 70,9% 68,6% 69,3% 70,7%  70,4% 
SG&A 17,2% 18,9% 18,6% 19,0% 19,0%  18,5% 
Other operating income 2% 7% 1% 2% 2%  3,0% 
Other operating expenses 2% 3% 1% 1% 1%  1,5% 
Restructuring expenses 0,3% 0,5% 0,2% 0,2% 0,8%  0,4% 
Interest income (% of Cash) 5,1% 5,1% 4,0% 1,5% 3,0%  3,8% 
Interest expense (% of Debt) 3,2% 2,0% 2,1% 2,1% 1,6%  1,6% 
 
Only revenues, EBIT and net income were adjusted, as Gerresheimer does not provide more information for a detailed “pre-acquisition” breakdown. 
Appendix 
61 
4. Historical Balance Sheet (1/2) 
Total Assets in Mio € 2014 2015 2016 2017 2018  CAGR  Sensile 2018 adjusted   CAGR adj.  
Intangible Assets 558 1.251 1.194 1.101 1.506  28,19%  (426) 1.080  17,98% 
Property, plant and equipment 579 605 610 603 621  1,75%  (1) 620  1,72% 
Investment property 4 6 6 6 5  4,54%  - 5  4,54% 
Investments accounted for using the equity method 0 0 0 0 0  36,32%  - 0  36,32% 
Income Tax receivables - 1 1 1 2  32,22%  - 2  32,22% 
other financial assets 6 5 5 5 4  -10,68%  - 4  -10,68% 
other receivables - 5 1 2 3  -18,31%  (0) 3  -18,49% 
deferred tax assets 7 8 14 11 19  27,91%  (8) 12  13,20% 
Long-term Assets 1.154 1.881 1.832 1.729 2.159  17,0%  (434) 1.725  10,58% 
         - -    
Inventories 194 186 155 148 171  -2,99%  - 171  -2,99% 
Trade receivables 208 219 232 243 274  7,03%  (9) 264  6,09% 
Income tax receivables 5 4 7 3 5  0,46%  - 5  0,46% 
other financial assets 3 11 11 17 18  18,32%  - 18  60,82% 
other receivables 24 24 19 18 22  -2,38%  (0) 22  -2,66% 
cash and cash equivalents 68 94 118 287 81  4,36%  161 241  37,27% 
Non-current assets and disposal groups held for sale - - - - 1    - 1   
Short-term Assets 502 538 543 715 572  3,30%  151 723  9,53% 
             




Historical Balance Sheet (2/2) 
Total Equity and Liabilities in Mio € 2014 2015 2016 2017 2018  CAGR  Sensile 2018 adjusted  CAGR adj. 
Subscribed capital 31 31 31 31 31  0,0%  - 31  0,00% 
capital reserve 514 514 514 514 514  0,0%  - 514  0,00% 
IAS 39 Reserve (0) (0) (0) (0) (0)  -61,1%  - (0)  -61,14% 
currency translation reserve (32) (32) (26) (71) (67)  20,7%  - (67)  20,68% 
retained earnings 30 113 207 279 395  90,3%  - 395  90,27% 
Equity attributable to equity holders of the parent 543 626 726 753 873  12,6%  - 873  12,57% 
non-controlling interests 61 72 37 36 17  -26,8%  (0) 17  -27,21% 
Equity 604 698 763 790 890  10,2%  (0) 890  10,15% 
              
Deferred tax liabilities 33 147 158 144 168  50,7%  (76) 92  29,59% 
provisions for pensions and similar obligations 170 158 160 145 142  -4,4%  (10) 132  -6,09% 
other provisions 5 7 8 10 11  19,1%  - 11  19,08% 
Trade payables - - - - 0   
 - 0    
other financial liabilities 386 741 745 681 751  18,1%  (74) 678  15,11% 
other liabilities 2 0 0 1 1  -27,3%  - 1  -27,28% 
Long-term Liabilities 596 1.054 1.070 981 1.072  15,8%  (159) 913  11,27% 
              
Provisions for pensions and similar obligations 14 19 14 14 14  0,1%  - 14  0,14% 
other provisions 56 65 53 35 45  -5,5%  (1) 44  -5,92% 
trade payables 125 161 157 176 207  13,4%  (2) 205  13,08% 
other financial liabilities 124 250 185 338 390  33,1%  (111) 278  22,33% 
income tax liabilities 22 55 25 9 5  -31,2%  (0) 5  -31,46% 
other liabilities 114 118 107 101 108  -1,4%  (9) 99  -3,56% 
Short-term Liabilities 456 668 541 673 768  13,9%  (123) 645  9,06% 
       
 
      




5. Revenues by Geography from 2014 - 2018 
in Mio. € 2014A 2015A 2016A 2017A 2018A  CAGR 
 Europe  467 467 458 429 460 
 -0,39% 
 y-y-growth in %  
 0,0% -1,8% -6,4% 7,2%   
 Germany  312 319 324 313 305 
 -0,60% 
 y-y-growth in %  
 2,1% 1,7% -3,4% -2,7%   
 America  262 245 363 374 375 
 9,40% 
 y-y-growth in %  
 -6,3% 48,1% 2,9% 0,3%   
 Emerging markets  217 220 204 207 207 
 -1,21% 
 y-y-growth in %  
 1,3% -7,3% 1,3% 0,1%   
 other regions  32 32 26 26 22 
 -9,26% 
 y-y-growth in %  
 0,3% -19,8% 0,4% -16,1%   
 Total  1.290 1.283 1.376 1.348 1.368 
 1,47% 
 
6. Revenue Forecasts - Drivers and Trends 
a) Plastic & Devices 
Drivers - Plastic & Devices weighting  2019E 2020E 2021E 2022E 2023E Mean 
 Generic drug growth  30% 2,9% 2,9% 2,9% 2,9% 2,9% 2,9% 
 Primary Pharma growth  30% 2,2% 2,2% 2,2% 2,2% 2,2% 2,2% 
 Rise in chronic diseases  10% 2,4% 2,6% 2,9% 3,2% 3,5% 2,9% 
 Healthcare in “Pharmerging Markets” 10% 3,7% 3,7% 3,9% 3,9% 3,9% 3,8% 
 Biotech- and Biosimilar products  10% 3,5% 3,5% 3,5% 3,5% 3,5% 3,5% 
 Self-Medication  10% 4,0% 4,0% 4,0% 4,0% 4,0% 4,0% 
 Plastic & Devices   2,9% 2,9% 3,0% 3,0% 3,0%  
 
b) Pharmaceutical Packaging Glass  
Drivers - Primary Packaging Glass weighting 2019E 2020E 2021E 2022E 2023E Mean 
 Generic drug growth  20% 2,6% 2,6% 2,6% 2,6% 2,6% 2,6% 
 Primary Pharma Growth  20% 2,2% 2,2% 2,2% 2,2% 2,2% 2,2% 
 Rise in chronic diseases  20% 2,1% 2,3% 2,6% 2,9% 3,2% 2,6% 
 Access to HC in PM  20% 3,2% 3,2% 3,4% 3,4% 3,4% 3,3% 
 Biotech and Biosimilar products  20% 2,0% 2,2% 2,4% 2,0% 2,0% 2,1% 
 Primary Packaging Glass   2,4% 2,5% 2,6% 2,6% 2,7%  
 
7. Non-recurring items 
Other operating income/expenses items are not subject to forecasts due to their status as “non-
recurring”. Furthermore, exchange gains and research and development costs, are also not 
considered in the forecasts given that almost no information is provided in the annual reports 




Other operating income   2014A 2015A 2016A 2017A 2018A 
income from refunds  5,80 2,45 1,66 4,22 13,30 
income from insurance reimbursements  6,38 
    
income from the derecognition of liabilities  1,08 1,48 3,50 6,09 5,99 
income from the reversal of provisions  1,83 5,69 5,54 9,18 4,68 
one-off income  0,22 77,00 0,99 0,28 1,09 
income from sale of scrap  0,68 0,80 0,73 0,83 1,07 
income from compensation payments  0,56 
    
income from other tax claims  
   2,55 0,06 
income from the disposal of asset  0,45 0,53 1,22 1,70 0,03 
income from the fair value measurement of put options 2,37   3,61  
exchange gains  
 0,62 0,46 0,39 0,23 
sundry other income   4,56 4,73 3,46 4,79 3,56 
Total other operating income   23,92 93,29 17,55 33,64 30,00 
 
 
     
Other operating expenses   2014A 2015A 2016A 2017A 2018A 
one-off expenses  1,74 21,20 1,50 2,90 11,03 
Research and development  1,50 1,85 3,16 3,51 2,92 
Expenses from network charges  
 1,16   1,35 
expenses from supervisory board remuneration 
and expense reimbursement 
 1,11 1,11 1,19 
loss from the fair value measurement of the put option   1,40  1,12 
loss from the disposal of fixed assets  0,39 0,72 0,39 0,27 0,30 
sundry other expenses  2,77 1,61 2,62 0,86 2,11 
Expenses from furnace damage  4,64 
    
Portfolio adjustments   12,60 8,96 1,03 
  
Total other operating expenses  23,64 35,50 11,22 8,65 20,02 
 
The EBITDA as reported was adjusted based on the values illustrated above, that cannot, 
following the reasoning of the author, be taken as an indicator for possible future economic 
performance. One can see that non-recurring items particularly in the light of divestments and 
one-off income resulted in a distorted view of the business. For example, in 2015, the company 
profited from the sale of the “glass tubing business” and gained additional 77 EURm. 
in Mio. €  2014A 2015A 2016A 2017A 2018A 
2018A 
adj. 
EBITDA as reported  234,9 306,2 306,6 305,6 276,5 273,6 
Less: other operating income  (23,9) (93,3) (17,6) (33,6) (30,0) (30,0) 
Pluss: other operating expenses  23,6 35,5 11,2 8,7 20,0 20,0 
net operating income/expenses  (0,3) (57,8) (6,3) (25,0) (10,0) (10,0) 
EBITDA adjusted  234,6 248,4 300,3 280,7 266,5 263,6 
adj. EBITDA-Margin  18,2% 19,4% 21,8% 20,8% 19,5% 19,5% 
        
EBIT as reported  129,9 181,9 180,5 180,8 139,5 146,9 
net operating income/expenses  (0) (58) (6) (25) (10) (10) 
EBIT adjusted  129,6 124,2 174,1 155,8 129,5 137,0 
adj. EBIT-Margin  10,0% 9,7% 12,7% 11,6% 9,5% 10,1% 
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8. Projected Income Statement: Core-Business 
in Mio. € 2019E 2020E 2021E 2022E 2023E CAGR 
Revenues 1.397 1.435 1.475 1.519 1.562 2,8% 
Cost of Sales (983) (1.010) (1.038) (1.069) (1.100) 2,8% 
Gross Profit 414 425 437 450 463 2,8% 
Gross margin 29,6% 29,6% 29,6% 29,6% 29,6%  
       
Selling and administration expense (263) (270) (273) (281) (289) 2,4% 
Other operating income 0,00 0,00 0,00 0,00 0,00   
Other operating expenses 0,00 0,00 0,00 0,00 0,00   
Restructuring expenses (11) (12) (6) (6) (6) -13,5% 
Share of profit/loss of associated companies 0,03 0,03 0,03 0,03 0,03 0,0% 
EBIT 139 143 158 162 167 4,6% 
EBIT Margin 10,0% 10,0% 10,7% 10,7% 10,7%  
Interest income 6 7 9 11 13 24,2% 
Interest expense (34) (35) (36) (38) (39) 4,0% 
Net finance expense (28) (28) (27) (26) (26) -1,8% 
NI before taxes 111 115 130 136 141 6,1% 
Taxes (31) (32) (36) (37) (39) 6,1% 
Net Incomes 81 83 94 98 102 6,1% 
       
D&A 124 133 141 141 143  
EBITDA 269 279 294 300 307  
EBITDA margin 19,2% 19,5% 20,0% 19,7% 19,7%  
       
Income Statement Assumptions       
 Revenue growth (y-o-y growth)   3,10% 2,72% 2,81% 2,95% 2,86%  
 Cogs (% margin)  70,38% 70,38% 70,38% 70,38% 70,38%  
 SG&A (% sales)  18,83% 18,83% 18,53% 18,53% 18,53%  
 Other expenses (% sales)  0,82% 0,82% 0,41% 0,41% 0,41%  
 EBIT margin  9,97% 9,97% 10,68% 10,68% 10,68%  
 Interest income (% cash)  2,00% 2,00% 2,00% 2,00% 2,00%  
 Interest expense (% debt)  3,08% 3,08% 3,08% 3,08% 3,08%  
 Tax-rate  27,60% 27,60% 27,60% 27,60% 27,60%  
 
9. Projected Balance sheet: Core-Business 
in Mio. € 2019E 2020E 2021E 2022E 2023E CAGR 
Intangible Assets 1.066 1.052 1.037 1.022 1.004 -1,5% 
Property, plant and equipment 684 732 738 744 765 2,8% 
Investment property 5 5 5 6 6 4,5% 
Investments (equity method) 0 1 1 1 1 36,3% 
Income Tax receivables 1 1 1 1 1 2,8% 
other financial assets 3 3 3 2 2 -10,7% 
other receivables 2 2 2 1 1 -18,3% 
deferred tax assets 11 11 11 12 12 2,8% 
Long-term Assets 1.773 1.806 1.797 1.789 1.794 0,3% 
       
Inventories 180 184 190 195 201 2,8% 
Trade receivables 246 253 260 268 275 2,8% 
Income tax receivables 5 5 5 6 6 2,8% 
other financial assets 24 33 45 61 83 35,8% 
other receivables 21 21 20 20 19 -2,4% 
cash and cash equivalents 248 296 406 518 620 25,8% 
Non-current assets held for sale 1 1 1 1 1 0,0% 
Short-term Assets 725 794 927 1.069 1.205 13,5% 
       
Total Assets 2.498 2.600 2.725 2.858 2.999 4,7% 
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in Mio. € 2019 2020 2021 2022 2023 CAGR 
Subscribed capital 31 31 31 31 31 0,0% 
capital reserve 514 514 514 514 514 0,0% 
IAS 39 Reserve (0) (0) (0) (0) (0) 0,0% 
currency translation reserve (71) (75) (79) (84) (88) 5,7% 
retained earnings 441 489 549 613 680 11,5% 
Equity of equity holders of the parent 915 960 1.015 1.074 1.137 5,6% 
non-controlling interests - - - - -  
Equity 915 960 1.015 1.074 1.137 5,6% 
       
Deferred tax liabilities 120 123 126 130 134 2,8% 
provisions for pensions and similar obligations 132 132 132 132 132 0,0% 
other provisions 11 11 11 11 11 0,0% 
Trade payables - - - - -  
other financial liabilities 700 737 781 828 876 5,8% 
other liabilities - - - - -  
Long-term Liabilities 963 1.003 1.051 1.101 1.153 4,6% 
       
Provisions for pensions and similar obligations 14 14 14 14 14 0,0% 
other provisions 44 44 44 44 44 0,0% 
trade payables 173 178 183 188 194 2,8% 
other financial liabilities 287 302 321 340 359 5,8% 
income tax liabilities 7 8 8 8 8 2,8% 
other liabilities 99 100 101 102 103 1,0% 
Short-term Liabilities 625 646 670 696 723 3,7% 
       
Total Equity and Liabilities 2.498 2.600 2.725 2.858 2.999 4,7% 
 
10. Projected Cash Flow Statement: Core-Business 
in €m 2019 2020 2021 2022 2023 
Net Profit 81 83 94 98 102 
D&A 129 136 137 138 140 
Other expenses (5) (3) (4) (4) (4) 
Change in NWC 13 (2) (2) (3) (3) 
Operating activities 218 214 225 229 236 
      
Capex (180) (170) (128) (129) (144) 
Change in fin. Assets (6) (9) (12) (16) (22) 
Change in other investments (0) (0) (0) (0) (0) 
Other (1) (1) (1) (1) (1) 
Investing Activities (187) (179) (141) (146) (167) 
      
Payment of dividend (35) (35) (35) (35) (35) 
Increases in long-term debt 20 34 42 45 48 
Increases in short-term debt 8 14 17 19 20 
NCI (18) - - - - 
Financing Activities (25) 13 25 29 33 
      
Change in Cash 6 49 109 112 102 
      
Cash BoP 241 248 297 406 518 
Change in Cash 6 49 109 112 102 





11. ROIC and re-formulated FCF 
in €m 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 
Invested Capital 1.146 1.867 1.815 1.715 1.709 1.759 1.792 1.783 1.775 1.779 
Total Assets 1.656 2.419 2.374 2.444 2.448 2.498 2.600 2.725 2.858 2.999 
Reinvestment Rate 69% 77% 76% 70% 70% 70% 69% 65% 62% 59% 
           
EBIAT 95 128 128 128 180 101 104 114 117 121 
ROIC 6,4% 11,2% 6,9% 7,1% 10,5% 5,9% 5,9% 6,4% 6,6% 6,8% 
WACC      5,6% 5,6% 5,6% 5,6% 5,6% 
 
in €m 2019 2020 2021 2022 2023 
EBIAT 101 104 114 117 121 
D&A 129 136 137 138 140 
Operating CF 230 240 251 255 261 
      
Fixed Assets 1.759 1.792 1.783 1.775 1.779 
Gross Capex Investment  (50) (33) 9 8 (4) 
Net Capex (179) (170) (128,0) (129) (144) 
NWC 13 (2)  (2) (3) (3) 
Core Business Cash Flow 63,5 68,2 120,6 122,9 114,1 
 
12. Dividend Yield 
in €m  2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 
Dividend/share  0,8 0,9 1,1 1,1 1,2 1,1 1,1 1,1 1,1 1,1 
Total  23,6 26,7 33,0 34,5 36,1 34,5 34,5 34,5 34,5 34,5 






Equation-10: Formula for dividend yield 
13. Working Capital derivation 




Equation-11: Days inventory on hands 




Equation-12: Days sales outstanding 




Equation-13: Days payable outstanding 
𝐶𝐶𝐶 (𝑐𝑎𝑠ℎ 𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 𝑐𝑦𝑐𝑙𝑒) = 𝐷𝐼𝐻 + 𝐷𝑆𝑂 − 𝐷𝑃𝑂 
Equation-14: Cash conversion cycle 
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Below, a summary of all working capital items assumptions is provided: 
in €m 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 
Accounts Receivable 208 219 232 243 274 246 253 260 268 275 
DSO 59 62 62 66 73 64 64 64 64 64 
Inventory 194 186 155 148 171 180 184 190 195 201 
DIH 76 75 60 58 65 67 67 67 67 67 
Prepaid Expenses 4 4 5 3 5 4 4 5 5 5 
% Sales 0,3% 0,3% 0,3% 0,2% 0,3% 0,3% 0,3% 0,3% 0,3% 0,3% 
Tax Receivable (s.t.) 5 4 7 3 5 5 5 5 6 6 
% Sales 0,4% 0,3% 0,5% 0,2% 0,4% 0,4% 0,4% 0,4% 0,4% 0,4% 
Tax Receivable (l.t.) - 1 1 1 2 1 1 1 1 1 
% Sales 0,0% 0,1% 0,1% 0,1% 0,1% 0,1% 0,1% 0,1% 0,1% 0,1% 
Accounts Payable 125 161 157 176 207 173 178 183 188 194 
DPO 49 65 61 69 78 64 64 64 64 64 
Prepayments received 44 31 30 28 35 35 36 37 38 39 
% Sales 3,4% 2,4% 2,2% 2,1% 2,6% 2,5% 2,5% 2,5% 2,5% 2,5% 
Tax Liability 22 55 25 9 5 7 8 8 8 8 
% Sales 1,7% 4,3% 1,8% 0,7% 0,4% 0,5% 0,5% 0,5% 0,5% 0,5% 
DTA 7 8 14 11 12 11 11 11 12 12 
% Sales 0,6% 0,6% 1,0% 0,8% 0,8% 0,8% 0,8% 0,8% 0,8% 0,8% 
DTL 33 147 158 144 120 123 126 130 134 120 
% Sales 2,5% 11,5% 11,5% 10,6% 8,6% 8,8% 8,8% 8,8% 8,8% 8,6% 
 
14. D&A and Capex overview 
in  €m 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 
Revenues 1.290 1.283 1.375 1.348 1.355 1.397 1.435 1.475 1.519 1.562 
PPE 579 605 610 603 620 684 732 738 744 765 
% of Sales 44,9% 47,1% 44,4% 44,7% 45,8% 49,0% 51,0% 50,0% 49,0% 49,0% 
Intangibles 558 1.251 1.194 1.101 1.080 1.066 1.052 1.037 1.022 1.004 
% of Sales 43,2% 97,5% 86,8% 81,7% 79,7% 76,3% 73,3% 70,3% 67,3% 64,3% 
           
Depreciation 86 82 85 89 92 104 112 112 113 117 
% of PPE 14,8% 13,6% 14,0% 14,8% 14,9% 15,3% 15,3% 15,3% 15,3% 15,3% 
Amortization 19 42 41 36 34 25 25 24 24 24 
% of Intangibles 3,5% 3,4% 3,4% 3,3% 3,2% 2,4% 2,4% 2,4% 2,4% 2,4% 
           
Capex PPE 123 122 109 99 109 169 159 118 120 138 
% of sales 9,5% 9,5% 7,9% 7,3% 8,0% 12,1% 11,1% 8,0% 7,9% 8,8% 
Capex Intang. 3 4 4 20 5 11 11 10 9 6 
% of sales 0,3% 0,3% 0,3% 1,5% 0,4% 0,8% 0,7% 0,7% 0,6% 0,4% 
           
Total D&A 105 124 126 125 127 129 136 137 138 140 





15. Derivation of tangibles and intangibles explicit period 
Intangibles 2019 2020 2021 2022 2023 
Intangibles BoP 1.080 1.066 1.052 1.037 1.022 
Amortization (25) (25) (24) (24) (24) 
Investments (capex) 11 11 10 9 6 
Intangibles EoP 1.066 1.052 1.037 1.022 1.004 
      
PP&E 2019E 2020E 2021E 2022E 2023E 
Tangibles BoP 620 684 732 738 744 
Depreciation (104) (112) (112) (113) (117) 
Investments (capex) 169 159 118 120 138 
Tangibles EoP 684 732 738 744 765 
 
16. CAPEX Projects Overview  
a) Main Growth Projects: 
 2019 2020 
Extension in Horsovsky Tyn (Czech Republic) X X 
North Macedonia X X 
New Facility Brazil Anapolis X X 
Extension in Wackersdorf (GER) X  
Bünde Projects (GER) X X 
Repair in Essen (GER) X  
Repair in Lohr (GER)  X 
Decoration Tettau (GER) X X 
Converting Machines in Poland and India X X 
 
b) Main Productivity Projects: 
 2019 2020 
Optimization of Packaging Syringes X  
Automation systems in Pfreimd (GER) X X 
Several automation packaging / packing / ampules / spraying projects X X 
Digitalization projects of PPG Systems  X X 
 
17. Gerresheimer’s production facilities  
Argentina Belgium Brazil 
China Denmark Germany 
France India Mexico 
Poland Singapore Czech Republic 
Spain Switzerland USA 
Appendix 
70 














Risk-free 0,31% 0,31% 0,31% 0,31% 0,31% 0,31% 0,31% 
MRP 7,00% 7,0% 7,0% 7,0% 7,0% 7,0% 7,0% 
Beta 
unlevered 
 0,88 0,91 0,85 0,88 0,91 0,85 
leverage 46,74% 0,47 0,47 0,47 0,47 0,47 0,47 
Tax rate 27,60% 27,6% 27,6% 27,6% 27,6% 27,6% 27,6% 
Beta levered  1,17 1,21 1,14 1,17 1,21 1,14 
Cost of 
Equity 
 8,5% 8,8% 8,3% 8,5% 8,8% 8,3% 
        
Risk-free -0,44% -0,4% -0,4% -0,4% -0,4% -0,4% -0,4% 
Spread 0,90% 0,90% 0,9% 0,9% 0,9% 0,9% 0,9% 
Cost of Debt  0,5% 0,5% 0,5% 0,5% 0,5% 0,5% 




 0,3% 0,3% 0,3% 0,3% 0,3% 0,3% 
        
Share Equity  68,1% 68,1% 68,1% 68,1% 68,1% 68,1% 
Share Debt  31,9% 31,9% 31,9% 31,9% 31,9% 31,9% 
WACC  5,9% 6,1% 5,8% 5,9% 5,8% 5,6% 
TV Growth 
rate 
2,25% 2,3% 2,3% 2,3% 2,3% 2,3% 2,3% 
TV WACC  3,7% 3,9% 3,5% 3,6% 3,5% 3,4% 
 
19. Yield Curves 
Risk-free rate* 1y 2y 3y 4y 5y 6y 7y 8y 9y 10 y 
30.11.2018 -0,653 -0,597 -0,550 -0,436 -0,270 -0,180 -0,062 0,064 0,182 0,309 
Corporate Bond**           
30.11.2018 -0,200 -0,010 0,230 0,460 0,690 0,890 1,090 1,270 1,430 1,580 
Credit Spread           
EUR Industrial 0,453 0,587 0,780 0,896 0,960 1,070 1,152 1,206 1,248 1,271 
 
*German Government Bond | ** EUR Industrial Corporate Bond 
 
-(0,653) -(0,597) -(0,550) 
-(0,436) 
-(0,270) -(0,180) 
-(0,062) 0,064  
0,182  0,309  





0,819  0,962  
1,034  1,105  
1  Y E A R 2  Y E A R S 3  Y E A R S 4  Y E A R S 5  Y E A R S 6  Y E A R S 7  Y E A R S 8  Y E A R S 9  Y E A R S 1 0  Y E A R S
YIELD CURVES 1Y-10Y
Federal Republic of Germany (Government) Corporate Bond - A Rated
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20. Effective tax rates 
effective tax rates 2014A 2015A 2016A 2017A 2018A 2019Q1 
 considering Tax loss carry forwards  26,7% 29,4% 28,9% 29,2% / / 
 no consideration of Tax loss carry forwards  26,7% 29,4% 28,9% 29,2% 27,6% 27,9% 
 







Cash Net Debt Leverage 
Tax 
Rate 
ßu Blume ßl 
William 
Demant 
6.673 955 84 870 13% 22% 0,73 0,82 0,74 
Ypsomed 1.451 82 31 51 4% 18% 0,57 0,71 0,69 
West Pharma 7.624 171 294 (123) -2% 27% 1,05 1,03 1,04 
PSB 125 65 79 (14) -11% 33% 0,52 0,68 0,74 
Consort 517 135 27 108 21% 19% 0,44 0,62 0,53 
Becton 
Dickinson 
58.586 18.372 997 17.375 30% 27% 0,99 0,99 0,81 
Draegerwerk 840 189 196 (7) -1% 30% 0,88 0,92 0,92 
Ansell 2.232 477 362 115 5% 30% 0,50 0,67 0,64 
AGC Inc 6.921 4.312 983 3.329 48% 31% 1,16 1,11 0,83 
          
median      0,99 0,99 0,83 
average      0,96 0,97 0,87 
weighted average     0,98 0,99 0,83 
 
The Reuters betas were pulled between April and Mai and are presented for comparison 
purposes only. Given that Reuters does not publish historical betas and that own regression 
analysis resulted in the exclusion of non-significant betas, the author assumes that Reuters betas 
might have limited accuracy. However, overall, they are fairly similar and the impact on the 
valuation is low. 
Company Name  Levered Beta Blume Adjustment Unlevered Beta 
 William Demant Holding A/S  1,00 1,00 0,91 
 Ypsomed Holding AG  0,66 0,77 0,75 
 West Pharmaceutical Services Inc  1,19 1,13 1,14 
 PSB Industries SA  0,78 0,85 0,92 
 Consort Medical PLC  0,48 0,65 0,56 
 Becton Dickinson and Co  0,97 0,98 0,81 
 Draegerwerk AG & Co KGaA  0,89 0,93 0,93 
 Ansell  1,10 1,07 1,03 
 AGC Inc  1,19 1,13 0,84 
    
Median 0,97 0,98 0,91 
Average 0,92 0,95 0,88 




22. Relative Valuation – complete Football field 
 
 


















Football field (share price) 











23. Relative Valuation - raw data overview 
 
Note: More technology-oriented peers trade substantially higher than contract manufacturing pharmaceutical packaging companies, where the up-
side potential is limited. As Gerresheimer will be able to shift its business into more profitable environments, applying higher multiples seems 
appropriate.   
Peer Group   
 EV / EBITDA    EV / Sales    EV / EBIT    P/E  
 FY0 FY1 FY2 FY3  FY0 FY1 FY2 FY3  FY0 FY1 FY2 FY3  FY0 FY1 FY2 FY3 
 Demant A/S   17,3 15,9 14,5 13,2  3,6 3,7 3,3 3,1  20,1 19,3 17,6 16,1  25,3 22,6 19,9 17,7 
 Ypsomed Holding AG   19,5 18,3 22,0 15,1  4,0 4,0 4,2 3,5  30,5 31,9 52,9 26,1  35,3 27,4 58,8 29,4 
 West Pharmaceutical Services Inc   20,1 21,7 20,1 17,9  4,1 4,6 4,4 4,1  28,6 30,6 26,3 23,7  36,2 40,9 35,3 31,5 
 PSB Industries SA   3,2 4,4 4,2 4,2  0,4 0,4 
  
 8,6 10,1 9,1   20,5 16,2 14,5  
 Consort Medical PLC   11,4 10,0 9,5 9,0  2,3 1,8 1,7 1,7  19,4 14,1 13,0 12,4  36,8 14,3 13,4 12,4 
 Becton Dickinson and Co   23,0 16,1 14,4 14,2  5,7 5,0 4,7 4,5  43,3 19,0 16,9 15,5  86,4 20,4 18,1 16,3 
 Draegerwerk AG & Co KGaA   7,9 7,6 6,2 5,4  0,5 0,4 0,4 0,4  17,9 17,7 12,0 9,4  32,2 29,4 17,9 14,1 
 Ansell Ltd   12,4 11,0 10,1 9,7  1,9 1,8 1,7 1,6  14,9 13,3 12,1 11,6  24,4 17,6 15,9 14,9 
 AGC Inc   5,5 5,4 5,0 4,8  0,9 0,9 0,9 0,9  11,1     8,6 10,9 9,7 8,9 
                      
                     
 Min   3,2 4,4 4,2 4,2  0,4 0,4 0,4 0,4  8,6 10,1 9,1 9,4  8,6 10,9 9,7 8,9 
 Max   23,0 21,7 22,0 17,9  5,7 5,0 4,7 4,5  43,3 31,9 52,9 26,1  86,4 40,9 58,8 31,5 
 Weighted average    20,3 15,5 14,0 13,4  4,8 4,3 4,1 3,9  36,1 18,5 16,8 15,0  67,3 21,7 19,7 17,3 
 Average   13,4 12,3 11,8 10,4  2,6 2,5 2,7 2,5  21,6 19,5 20,0 16,4  34,0 22,2 22,6 18,2 
 Median    12,4 11,0 10,1 9,7  2,3 1,8 2,5 2,4  19,4 18,4 15,0 15,5  32,2 20,4 17,9 15,6 
 0,25 Quartile   6,7 6,5 5,6 5,1  0,7 0,7 1,1 1,1  13,0 13,5 12,0 11,6  22,5 15,3 14,0 12,9 
 0,75 Quartile   19,8 17,2 17,3 14,6  4,1 4,3 4,3 4,0  29,6 27,7 24,1 23,7  36,5 28,4 27,6 26,5 






 EV / EBITDA  EV / Sales  EV / EBIT  P / E 
 2018 2019 2020 2021  2018 2019 2020 2021  2018 2019 2020 2021  2018 2019 2020 2021 
Metric  274 266 273 291  1.355 1.397 1.435 1.475  147 139 143 158  138 81 83 93 
                     
Min  883 1.173 1.142 1.218  497 586 622 615  1.270 1.410 1.295 1.479  1.192 882 800 825 
Max  6.305 5.781 6.016 5.228  7.748 6.958 6 787 6.628  6.362 4.439 7.572 4.105  11.947 3.309 4.863 2.927 
Weighted average  5.557 4.112 3.829 3.910  6.513 6.069 5 913 5.757  5.308 2.583 2.404 2.363  9.309 1.757 1.632 1.609 
Average  3.659 3.263 3.218 3.025  3.518 3.508 3 840 3.661  3.176 2.716 2.859 2.581  4.695 1.795 1.871 1.688 
Median  3.388 2.917 2.757 2.820  3.056 2.474 3 625 3.507  2.848 2.558 2.139 2.442  4.452 1.649 1.480 1.452 
0,25 Quartile  1.833 1.731 1.539 1.494  903 954 1 572 1.575  1.910 1.877 1.722 1.821  3.107 1.235 1.155 1.196 
0,75 Quartile  5.423 4.567 4.724 4.257  5.507 6.036 6 230 5.885  4.345 3.863 3.448 3.729  5.041 2.297 2.286 2.463 
                     
Gerresheimer 
Share price 
 EV / EBITDA  EV / Sales  EV / EBIT  P / E* 
 2018 2019 2020 2021  2018 2019 2020 2021  2018 2019 2020 2021  2018 2019 2020 2021 
Min  2 12 11 13  0 0 0 0  15 19 15 21  38 28 25 26 
Max  175 158 166 141  221 196 189 185  177 116 215 105  380 105 155 93 
Weighted average  151 105 96 99  182 168 162 158  143 57 51 49  296 56 52 51 
Average  91 78 77 71  86 86 96 91  75 61 65 56  150 57 60 54 
Median  82 67 62 64  72 53 89 86  65 56 42 52  142 53 47 46 
0,25 Quartile  33 29 23 22  3 5 23 24  35 34 29 32  99 39 37 38 
0,75 Quartile  147 120 125 110  150 166 172 162  113 97 84 93  161 73 73 78 
                     
Equity / enterprise value in €m | share price in € 
 
Note: 
1) Enterprise Value multiples include Atech. Thus, they represent the whole Business of Gerersheimer 
2) P/E-multiples refer to the equity-value of Plastic & Devices and Pharmaceutical Packaging Glass. 
3) Using 2y-forward multiples yields the most preferred result, in line with literature review. 
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24. Relative Valuation – consensus estimates  
Below, consensus estimates of the financial metrics were pulled from Reuters. Since the PE multiples are based on the “sum of the parts”- Net 
Income, one could not arrive at a consolidated share price. (consensus is highlighted in yellow). The 2y-forward multiples are considered as most 
relevant in line with literature review and are highlighted in light blue. 
Gerresheimer  
Relative Valuation (consolidated) 
 EV / EBITDA  EV / Sales  EV / EBIT  P/E 
 2018 2019 2020 2021  2018 2019 2020 2021  2018 2019 2020 2021  2018 2019 2020 2021 
Metric (@ Reuters)  277 314 318 355  1.368 1.434 1.515 1.607  139 196 168 199  131 125 125 152 
                     
Min  892 1.386 1.329 1.483  501 601 656 670  1.205 1.986 1.522 1.869  1.131 1.362 1.206 1.352 
Max  6.373 6.826 7.001 6.367  7.822 7.143 7.166 7.220  6.038 6.255 8.901 5.186  11.335 5.106 7.326 4.800 
Weighted average  5.617 4.856 4.455 4.763  6.575 6.230 6.243 6.271  5.038 3.640 2.826 2.985  8.831 2.711 2.458 2.638 
Average  3.698 3.853 3.744 3.684  3.552 3.601 4.054 3.988  3.014 3.827 3.361 3.261  4.454 2.769 2.819 2.769 
Median  3.424 3.445 3.208 3.435  3.085 2.540 3.828 3.820  2.703 3.604 2.514 3.086  4.223 2.545 2.230 2.381 
0,25 Quartile  1.853 2.044 1.791 1.819  912 979 1.660 1.716  1.813 2.645 2.024 2.301  2.948 1.906 1.741 1.961 
0,75 Quartile  5.481 5.393 5.498 5.184  5.560 6.196 6.578 6.411  4.124 5.444 4.054 4.712  4.782 3.544 3.444 4.039 
                     
Gerresheimer share price  
(consensus) 
 EV / EBITDA  EV / Sales  EV / EBIT  P/E 
 2018 2019 2020 2021  2018 2019 2020 2021  2018 2019 2020 2021  2018 2019 2020 2021 
Min  - 6 5 10  - - - -  1 26 11 22  36 43 38 43 
Max  165 180 185 165  211 190 191 192  155 162 246 127  361 163 233 153 
Weighted average  141 117 104 114  172 161 161 162  123 78 52 57  281 86 78 84 
Average  80 85 82 80  75 77 91 89  58 84 69 66  142 88 90 88 
Median  71 72 64 72  61 43 84 84  48 77 42 61  135 81 71 76 
0,25 Quartile  21 27 19 20  - - 15 17  20 47 27 36  94 61 55 62 
0,75 Quartile  137 134 137 127  139 160 172 166  94 136 91 112  152 113 110 129 




25. Relative Valuation – complete Football field (consensus) 
 
 


















Football field (share price) 
 25th to Median  Median to 75th
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Gerresheimer 2.248 3.486 1.587 474 328 21% 175 113 1,6% 4,2% 1,11 2,72 30 11 5,8                 
Carl Zeiss Meditec AG 7.803 7.848 1.487 825 269 18,1% 233 147 7,2% 15% 0,02 0 2 113 98 
Sartorius AG 11.763 13.033 1.796 NULL 313 17% 310 206 10,7% 11% 1,62 2 13 24 24 
Fresenius Medical Care AG & Co KGaA 23.397 31.089 21.333 7.202 3.674 17% 2.792 1.535 10,2% 11% 0,76 2 476 8 6 
Draegerwerk AG & Co KGaA 917 952 2.982 NULL 182 6% 85 45 1,6% 11% 0,20 0 9 20 9 
Siemens Healthineers AG 39.427 38.743 15.588 6.347 3.102 20% 2.485 1.468 3,2% 19% 0,01 NULL 238 13 10 
Koninklijke Philips NV 36.204 39.394 20.783 9.809 3.483 17% 2.234 1.250 -3,8% 12% 0,40 1 222 16 10 
Coltene Holding AG 575 578 172 125 32 19% 26 20 1,2% 19% 0,07 0 0 103 84 
Coloplast A/S 18.775 19.199 2.560 1.722 898 35% 800 598 7,2% 61% 0,21 0 2 481 428 
Smith & Nephew PLC 16.418 17.476 4.904 3.606 1.464 30% 1.010 663 2,4% 17% 0,30 1 49 30 21 
Straumann Holding AG 11.695 11.651 1.141 865 334 29% 293 280 10,1% 23% 0,19 NULL 6 54 47 
William Demant Holding A/S 8.434 9.293 2.126 1.621 459 22% 394 283 9,0% 15% 0,75 2 11 41 35 
Ypsomed Holding AG 1.515 1.572 489 147 100 20% 64 55 13,8% 15% 0,17 0 0 294 188 
AGC Inc 7.968 12.808 13.900 3.832 2.215 16% 1.105 818 2,9% 6% 0,48 2 64 35 17 
Compagnie de Saint Gobain SA 19.454 30.388 48.956 12.464 4.986 10% 3.539 1.879 -1,1% 11% 0,50 2 357 14 10 
Berry Global Group Inc 6.718 12.165 7.869 1.431 1.335 17% 797 496 11,1% 9% 4,08 4 253 5 3 
Nippon Sheet Glass Co Ltd 771 4.268 5.683 1.524 638 11% 337 58 3,0% 2% 2,74 5 145 4 2 
West Pharmaceutical Services Inc 7.475 7.374 1.717 545 345 20% 240 207 4,7% 15% 0,15 NULL 7 49 34 
PSB Industries SA 128 129 316 NULL 57 18% 27 11 8,8% 4% 0,80 0 3 19 9 
Consort Medical PLC 562 683 428 NULL 85 20% 50 22 26,8% 6% 0,47 2 4 19 11 
Nipro Corp 2.296 6.084 3.721 1.196 594 16% 255 111 10,4% 2% 2,97 8 33 18 8 
Becton Dickinson and Co 65.789 85.914 15.983 7.262 3.966 25% 2.111 311 14,7% 8% 1,02 4 706 6 3 
Sonova Holding AG 12.244 12.601 2.775 1.959 662 24% 521 420 8,1% 16% 0,31 0 1 494 389 
Zignago Vetro SpA 967 1.136 313 241 78 25% 41 48 -2,7% 14% 1,05 2 2 39 21 
Thermo Fisher Scientific Inc 89.991 106.847 24.358 10.859   6.143 25% 3.876 2.938 13,2% 6% 0,69 3 667 9 6 
Ansell 2.522 2.665 1.493 583 229 16% 158 120 4,2% 6% 0,36 1 20 11 8 
all Values in Million US Dollar @Reuters, based on February 20, 2019           
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27. Peer group derivation – results  
 
Peer Group is highlighted   
 
Company name Business / Product EBITDA Margin Debt / Equity Rating ROIC CAGR  Total Score 
Carl Zeiss Meditec AG 2 1 3 2 2 2  12 
Sartorius AG 2 2 1 2 2 2  11 
Fresenius Medical Care AG & Co KGaA 3 2 1 1 2 2  n/a 
Draegerwerk AG & Co KGaA 1 3 2 1 2 1  10 
Siemens Healthineers AG 2 1 3 2 3 2  13 
Koninklijke Philips NV 2 2 2 2 2 3  13 
Coltene Holding AG 2 1 3 2 3 1  12 
Coloplast A/S 2 3 2 2 3 2  14 
Smith & Nephew PLC 2 3 2 2 3 1  13 
Straumann Holding AG 2 3 2 2 3 2  14 
William Demant Holding A/S 2 1 1 2 2 2  10 
Ypsomed Holding AG 1 1 2 2 2 2  10 
AGC Inc 1 2 2 2 2 1  10 
Compagnie de Saint Gobain SA 2 3 2 2 2 3  14 
Berry Global Group Inc 2 2 3 1 2 2  12 
Nippon Sheet Glass Co Ltd 3 3 3 3 2 1  n/a 
West Pharmaceutical Services Inc 1 1 2 2 2 2  10 
PSB Industries SA 2 2 1 1 1 2  9 
Consort Medical PLC 1 1 2 2 1 3  10 
Nipro Corp 2 2 3 1 1 2  11 
Becton Dickinson and Co 1 2 1 2 2 2  10 
Sonova Holding AG 2 1 2 2 3 2  12 
Zignago Vetro SpA 3 2 1 2 2 3  n/a 
Thermo Fisher Scientific Inc 3 2 1 1 1 2  n/a 
Ansell 1 2 2 2 1 2  10 
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28. Histogram – Monte Carlo  
 
z bins  Buy: X > 75 Hold: 55,1 < X > 74,9 Sell: X < 55 
-(4,50) 22,8 -   - 
-(4,00) 28,7 -   - 
-(3,50) 34,6 -   - 
-(3,00) 40,5 2   2 
-(2,50) 46,5 36   36 
-(2,00) 52,4 140   140 
-(1,50) 58,3 399  399  
-(1,00) 64,2 983  983  
-(0,50) 70,1 1.593  1.593  
- 76,0 2.022 2.022   
0,5 82,0 1.862 1.862   
1,0 87,9 1.365 1.365   
1,5 93,8 875 875   
2,0 99,7 437 437   
2,5 105,6 181 181   
3,0 111,5 73 73   
3,5 117,5 20 20   
4,0 123,4 9 9   
4,5 129,3 3 3   
 
29. GDP and Inflation rates of the German economy 
  2018 2019 2020 2021 2022 2023 
Inflation 1,80% 1,80% 2,10% 2,30% 2,50% 2,20% 
Real GDP 1,90% 1,90% 1,60% 1,50% 1,30% 1,20% 
Nominal GDP 3,70% 3,70% 3,70% 3,80% 3,80% 3,40% 
 
30. Terminal Value Sensitivities 
a) Possible Terminal Value growth rates and the corresponding share prices 
  
Company driver Industry growth Inflation / IQVIA Thesis GDP   





 4,6% 89 102 119 122 259 
5,1% 73 82 94 96 174 
5,6% 60 68 76 €78  128 
6,1% 51 56 63 64 99 





b) Implied growth rates arrived by applying different Exit-Multiples 
The Multiples used for the Exit-Multiple model are based on the EV/EBTIDA 2019 multiples 






31. Investment Bank Recommendations  
All Investment Bank reports refer to the data published in the latest available annual report 
(2018). As illustrated below, there is no clear consensus about target price, and it appears that 
Gerresheimer is not the most favored among analysts. One reason for that might be that the 
company lacked of convincing underlying growth performance and analysts argued in their 
reports that communication and management execution was not ideal. However, the author does 
not consider analysts’ sensations of Gerresheimer´s former management to be relevant for the 
purpose of this thesis and is therefore confident that the company can substantially increase 


































Hock & Aufhaeuser (H&A) predicted the lowest share price for Gerresheimer among the 
investment banks. Therefore, it is worth to analyse the reasons behind this sentiment. The target 
price of 50 € was compared to the price of 68,70 € as of 07 March 2019. The sell-
recommendation is based on the ill positioning of Gerresheimer in the industry in order to 
sustainable increase sales growth. H&A describes the company as being exposed to price 
pressure and slow growth in the pharma market.  
The main difference between the CS, H&A and the model of this thesis is, is that H&A applied 
a relatively low EV/Sales multiple of 1,6x, which is not in line with the peer-group. A 
summarising table with the main valuation-assumptions is provided on the next page. 
 
 Hock & Aufhäuser This thesis 
Target  50€ (down to sell) 78€ (outperform) 
Methodology Multiples – Sotp (H&A applied an 
EV/Sales multiple of 1,6x on 2020 
Revenues) 
DCF – Sotp 
EV/Revenue 
peers 
Peer group suggests a Revenue multiple (forward 2020) that varies 
between 2,5 (median) and 4,1 (weighted average) with an overall 








1461,9 EURm 1435,9 EURm 
WACC 7,5% (implied IRR) 5,6% 
 
32. Synthetic Rating Damodaran (2019) 
For all emerging market firms and developed market 
firms with market cap < $5 billion  
 For developed market firms with market cap > $5 
billion  
 If interest coverage ratio is       If interest coverage ratio is      
 greater than   ≤ to   Rating is   Spread is   >   ≤ to   Rating is   Spread is  
- (100.000,00)                 0,50    D2/D   19.38%  - (100.000,00)                 0,20    D2/D   19.38%  
                 0,50                  0,80    C2/C   14.54%                   0,20                  0,65    C2/C   14.54%  
                 0,80                  1,25    Ca2/CC   11.08%                   0,65                  0,80    Ca2/CC   11.08%  
                 1,25                  1,50    Caa/CCC   9.00%                   0,80                  1,25    Caa/CCC   9.00%  
                 1,50                  2,00    B3/B-   6.60%                   1,25                  1,50    B3/B-   6.60%  
                 2,00                  2,50    B2/B   5.40%                   1,50                  1,75    B2/B   5.40%  
                 2,50                  3,00    B1/B+   4.50%                   1,75                  2,00    B1/B+   4.50%  
                 3,00                  3,50    Ba2/BB   3.60%                   2,00                  2,25    Ba2/BB   3.60%  
                 3,50                  4,00    Ba1/BB+   3.00%                   2,25                  2,50    Ba1/BB+   3.00%  
                 4,00                  4,50    Baa2/BBB   2.00%                   2,50                  3,00    Baa2/BBB   2.00%  
                 4,50                  6,00    A3/A-   1.56%                   3,00                  4,25    A3/A-   1.56%  
                 6,00                  7,50    A2/A   1.38%                   4,25                  5,50    A2/A   1.38%  
                 7,50                  9,50    A1/A+   1.25%                   5,50                  6,50    A1/A+   1.25%  
                 9,50                12,50    Aa2/AA   1.00%                   6,50                  8,50    Aa2/AA   1.00%  




33. Complete DCF summary 
Free Cash Flow 
Currency: € Mio 2013A 2014A 2015A 2016A 2017A 2018A 2019E 2020E 2021E 2022F 2023F TV CAGR 14-23 CAGR 14-18 CAGR 19-23
Revenues 1.266 1.290 1.283 1.375 1.348 1.355 1.397 1.434,9 1.475 1.519 1.562 1.597 2,15% 1,23% 2,84%
Revenue growth y-o-y in %  1,9%  (0,6%)  7,2%  (2,0%)  0,5%  3,1%  2,7%  2,8%  3,0%  2,9%  2,25%
EBITDA 235 306 307 306 274 269 279 294 300 307 314 3,03% 3,89% 3,40%
EBITDA Margin  18,2%  23,9%  22,3%  22,7%  20,2%  19,2%  19,5%  20,0%  19,7%  19,7%  19,7%
Depreciation & Amortisation (105) (124) (126) (125) (127) (129) (136) (137) (138) (140) (144) 3,28% 4,80% 2,04%
EBIT 130 182 180 181 147 139 143 158 162 167 170 2,82% 3,13% 4,62%
EBIT Margin  10,1%  14,2%  13,1%  13,4%  10,8%  10,0%  10,0%  10,7%  10,7%  10,7%  10,7%
 
EBIT 130 182 180 181 147 139 143 158 162 167 170
less: Taxes (35) (54) (52) (53) 33 (38) (39) (43) (45) (46) (47)
EBIAT (Earnings Before Interest After Taxes) 95 128 128 128 180 101 104 114 117 121 123 2,68% 17,20% 4,62%
Plus: Depreciation & Amortisation 105 124 126 125 127 129 136 137 138 140 144 3,28% 4,80% 2,04%
Less: Capital Expenditures (127) (126) (113) (119) (114) (180) (170) (128) (129) (144) (144) 1,44% -2,53% -5,37%
Less/Plus: Change in Working Capital 44,2 172,0 (17,9) (22,1) (66,0) 12,6 (2,1) (2,3) (2,7) (2,7) (0,2)
FCFF - Core Business 118 299 123 112 126 63 68 121 123 114 123 -0,33% 1,70% 15,92%
DCF Model
Currency: € '000 2019E 2020E 2021E 2022F 2023F TV
Free Cash Flow 63 68 121 123 114 123 1,9% 2,1% 2,3% 2,5% 2,7%
Partial year adjustment 1,0 1,0 1,0 1,0 1,0 1,0 4,6% 102 111 122 135 150
Free Cash Flow, adjusted 63 68 121 123 114 123 5,1% 82 89 96 104 114
5,6% 68 72 77,52 €         83 90
WACC  5,6%  5,6%  5,6%  5,6%  5,6%  3,4% 6,1% 56 60 64 68 73
mid year discounting 0,5 1,5 2,5 3,5 4,5 5,5 6,6% 48 50 53 57 60
Present value factor 0,97 0,92 0,87 0,83 0,78 23,23
Present Value of the Free Cash Flows 62 63 105 102 89 2.861,5
Enterprise Value PPG and P&D 3.282,4 87,2%
Enterprise Value Advanced Technologies 334,8
Group Enterprise Value 3.617,1
Plus: Cash 80
Less: Debt (1.003)
Less: Noncontrolling Interests (76)
Less: Pensions and others (184)
Total Adjustments to EV (1.183)
Equity Value as per 30.11.2018 2.434
Shares Outstanding as of 30.11.2018 31,4
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